JP2018528977A - カンナビノイドグリコシドプロドラッグおよび合成の方法 - Google Patents
カンナビノイドグリコシドプロドラッグおよび合成の方法 Download PDFInfo
- Publication number
- JP2018528977A JP2018528977A JP2018516020A JP2018516020A JP2018528977A JP 2018528977 A JP2018528977 A JP 2018528977A JP 2018516020 A JP2018516020 A JP 2018516020A JP 2018516020 A JP2018516020 A JP 2018516020A JP 2018528977 A JP2018528977 A JP 2018528977A
- Authority
- JP
- Japan
- Prior art keywords
- cannabinoid
- ugt76g1
- glycoside
- udp
- glucosyltransferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 253
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 253
- 229930182470 glycoside Natural products 0.000 title claims abstract description 204
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 193
- 239000000651 prodrug Substances 0.000 title claims abstract description 81
- 229940002612 prodrug Drugs 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims description 100
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 138
- 230000013595 glycosylation Effects 0.000 claims abstract description 124
- 102000051366 Glycosyltransferases Human genes 0.000 claims abstract description 58
- 108700023372 Glycosyltransferases Proteins 0.000 claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 claims abstract description 46
- 101100262416 Stevia rebaudiana UGT76G1 gene Proteins 0.000 claims description 119
- 108010055629 Glucosyltransferases Proteins 0.000 claims description 91
- 102000000340 Glucosyltransferases Human genes 0.000 claims description 91
- 150000001875 compounds Chemical class 0.000 claims description 87
- -1 β-D-glucopyranosyl Chemical group 0.000 claims description 77
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 66
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 66
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 claims description 66
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 66
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 claims description 60
- 235000000346 sugar Nutrition 0.000 claims description 45
- 108010043934 Sucrose synthase Proteins 0.000 claims description 32
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 239000002621 endocannabinoid Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 25
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims description 23
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims description 21
- 229920002774 Maltodextrin Polymers 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 239000005913 Maltodextrin Substances 0.000 claims description 18
- 229940035034 maltodextrin Drugs 0.000 claims description 18
- 235000019202 steviosides Nutrition 0.000 claims description 13
- 239000004383 Steviol glycoside Substances 0.000 claims description 11
- 229930182488 steviol glycoside Natural products 0.000 claims description 11
- 235000019411 steviol glycoside Nutrition 0.000 claims description 11
- 150000008144 steviol glycosides Chemical class 0.000 claims description 11
- 239000005715 Fructose Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 7
- 230000008499 blood brain barrier function Effects 0.000 claims description 7
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 7
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003599 detergent Substances 0.000 claims description 6
- HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 claims description 6
- DQQDLYVHOTZLOR-OCIMBMBZSA-N UDP-alpha-D-xylose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1OC[C@@H](O)[C@H](O)[C@H]1O DQQDLYVHOTZLOR-OCIMBMBZSA-N 0.000 claims description 5
- DQQDLYVHOTZLOR-UHFFFAOYSA-N UDP-alpha-D-xylose Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OCC(O)C(O)C1O DQQDLYVHOTZLOR-UHFFFAOYSA-N 0.000 claims description 5
- HSCJRCZFDFQWRP-NYYOCOOHSA-N [[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-NYYOCOOHSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- DRDCJEIZVLVWNC-SLBWPEPYSA-N UDP-beta-L-rhamnose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 DRDCJEIZVLVWNC-SLBWPEPYSA-N 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000012459 cleaning agent Substances 0.000 claims 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 110
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 99
- 229950011318 cannabidiol Drugs 0.000 description 99
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 99
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 98
- 150000007523 nucleic acids Chemical class 0.000 description 57
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 55
- 108020004707 nucleic acids Proteins 0.000 description 54
- 102000039446 nucleic acids Human genes 0.000 description 54
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 52
- 239000000047 product Substances 0.000 description 52
- 230000000694 effects Effects 0.000 description 44
- 229940065144 cannabinoids Drugs 0.000 description 42
- 229960004242 dronabinol Drugs 0.000 description 40
- 102000004190 Enzymes Human genes 0.000 description 37
- 108090000790 Enzymes Proteins 0.000 description 37
- 241000196324 Embryophyta Species 0.000 description 34
- 239000012634 fragment Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 29
- 238000004128 high performance liquid chromatography Methods 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 244000228451 Stevia rebaudiana Species 0.000 description 23
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 23
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical class C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 21
- 108010029485 Protein Isoforms Proteins 0.000 description 21
- 102000001708 Protein Isoforms Human genes 0.000 description 21
- 210000002429 large intestine Anatomy 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 17
- 239000000758 substrate Substances 0.000 description 16
- WVMKYAHQZYCCCX-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-n-(2-hydroxyethyl)docosa-2,4,6,8,10,12-hexaenamide Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)NCCO WVMKYAHQZYCCCX-SKCDLICFSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000007795 chemical reaction product Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 235000017663 capsaicin Nutrition 0.000 description 14
- 229960002504 capsaicin Drugs 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 229960003453 cannabinol Drugs 0.000 description 13
- 230000014759 maintenance of location Effects 0.000 description 13
- 241000218236 Cannabis Species 0.000 description 12
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 12
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 229920002125 Sokalan® Polymers 0.000 description 12
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 12
- GEEHOLRSGZPBSM-KUBAVDMBSA-N N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCO GEEHOLRSGZPBSM-KUBAVDMBSA-N 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 235000012141 vanillin Nutrition 0.000 description 11
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 101100101355 Stevia rebaudiana UGT91D1 gene Proteins 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 101100262417 Stevia rebaudiana UGT76H1 gene Proteins 0.000 description 8
- 101100101356 Stevia rebaudiana UGT91D2 gene Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 8
- 235000012754 curcumin Nutrition 0.000 description 8
- 239000004148 curcumin Substances 0.000 description 8
- 229940109262 curcumin Drugs 0.000 description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 101000874334 Dalbergia nigrescens Isoflavonoid 7-O-beta-apiosyl-glucoside beta-glycosidase Proteins 0.000 description 7
- 101000757733 Enterococcus faecalis (strain ATCC 700802 / V583) Autolysin Proteins 0.000 description 7
- 101000757734 Mycolicibacterium phlei 38 kDa autolysin Proteins 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000235058 Komagataella pastoris Species 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 101710204244 Processive diacylglycerol beta-glucosyltransferase Proteins 0.000 description 6
- 101100427140 Stevia rebaudiana UGT74G1 gene Proteins 0.000 description 6
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 6
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 238000001784 detoxification Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 210000004248 oligodendroglia Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000003566 TRPV1 Human genes 0.000 description 5
- 101150016206 Trpv1 gene Proteins 0.000 description 5
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 5
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 201000009032 substance abuse Diseases 0.000 description 5
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- YKGQBEGMUSSPFY-YOILPLPUSA-N Mead acid-EA Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(=O)NCCO YKGQBEGMUSSPFY-YOILPLPUSA-N 0.000 description 4
- 108700027408 O-acetylhomoserine (thiol)-lyase Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 101000808808 Stevia rebaudiana UDP-glycosyltransferase 74G1 Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000013583 drug formulation Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 3
- 108050007331 Cannabinoid receptor Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 description 3
- 101150065537 SUS4 gene Proteins 0.000 description 3
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 3
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 238000003353 bioavailability assay Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinyl group Chemical group C1(O)=CC(O)=CC=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical group C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 3
- 229940032084 steviol Drugs 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 229940117960 vanillin Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OVKKNJPJQKTXIT-JLNKQSITSA-N (5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO OVKKNJPJQKTXIT-JLNKQSITSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
- WDXXEUARVHTWQF-DLBZAZTESA-N 3-hydroxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(CCCCC)=CC(=O)C([C@H]2[C@@H](CCC(C)=C2)C(C)=C)=C1O WDXXEUARVHTWQF-DLBZAZTESA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 2
- 101100137815 Arabidopsis thaliana PRP8A gene Proteins 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 101000920618 Homo sapiens Transcription and mRNA export factor ENY2 Proteins 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- UHPXXKLAACDXGS-UHFFFAOYSA-N Pentadecanoyl-EA Chemical compound CCCCCCCCCCCCCCC(=O)NCCO UHPXXKLAACDXGS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000007643 Phytolacca americana Species 0.000 description 2
- 235000009074 Phytolacca americana Nutrition 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 101150085660 SUS2 gene Proteins 0.000 description 2
- 101150000971 SUS3 gene Proteins 0.000 description 2
- 101150010777 SUS5 gene Proteins 0.000 description 2
- 101150067292 SUS6 gene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 102000003610 TRPM8 Human genes 0.000 description 2
- 108010062740 TRPV Cation Channels Proteins 0.000 description 2
- 102000011040 TRPV Cation Channels Human genes 0.000 description 2
- 102000003565 TRPV2 Human genes 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102100031954 Transcription and mRNA export factor ENY2 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 101150111302 Trpm8 gene Proteins 0.000 description 2
- 101150077905 Trpv2 gene Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 244000213578 camo Species 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 229930191614 cannabinolic acid Natural products 0.000 description 2
- KXKOBIRSQLNUPS-UHFFFAOYSA-N cannabinolic acid A Natural products O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- QSIDJGUAAUSPMG-CULFPKEHSA-N steviolmonoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QSIDJGUAAUSPMG-CULFPKEHSA-N 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000954177 Bangana ariza Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000841500 Homo sapiens UDP-glucuronosyltransferase 1A10 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- LISKWSFNVJTQKH-KTKRTIGZSA-N N-(15Z-tetracosenoyl)ethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)NCCO LISKWSFNVJTQKH-KTKRTIGZSA-N 0.000 description 1
- JHIXEZNTXMFXEK-UHFFFAOYSA-N N-(tetradecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCC(=O)NCCO JHIXEZNTXMFXEK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 206010036775 Rectal inflammations Diseases 0.000 description 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101100262693 Solanum melongena GT gene Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101100048059 Stevia rebaudiana UGT85C2 gene Proteins 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- WFRQXTUCHBFZII-UHFFFAOYSA-N Tricosanoyl-EA Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)NCCO WFRQXTUCHBFZII-UHFFFAOYSA-N 0.000 description 1
- 108010067922 UDP-Glucuronosyltransferase 1A9 Proteins 0.000 description 1
- 102100040212 UDP-glucuronosyltransferase 1A9 Human genes 0.000 description 1
- 102100029819 UDP-glucuronosyltransferase 2B7 Human genes 0.000 description 1
- 101710200333 UDP-glucuronosyltransferase 2B7 Proteins 0.000 description 1
- 102100020797 UMP-CMP kinase Human genes 0.000 description 1
- 102100038834 UTP-glucose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- 108700023183 UTP-glucose-1-phosphate uridylyltransferases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
- 101710166980 Uridylate kinase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102220515664 Zinc finger protein Helios_S13D_mutation Human genes 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical class C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010667 large scale reaction Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- DUBCCGAQYVUYEU-ZUGPOPFOSA-N miquelianin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O DUBCCGAQYVUYEU-ZUGPOPFOSA-N 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- SKDZEPBJPGSFHS-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)N(CCO)CCO SKDZEPBJPGSFHS-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 102220198520 rs145392673 Human genes 0.000 description 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 1
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000215338 unidentified plant Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000008135 α-glycosides Chemical class 0.000 description 1
- 150000008136 β-glycosides Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
【選択図】図1A
Description
(式中、Rは、H、β‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;
R’は、H、またはβ‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;かつ
Aは、カンナビノイド化合物、エンドカンナビノイド化合物、もしくはバニロイド化合物の、ヒドロキシル基の反応を通して形成されたアグリコン部分構造である。)。
CB カンナビノイド
CBD カンナビジオール
CBDV カンナビジバリン
CBG カンナビゲロール
Δ9‐THCまたはTHC テトラヒドロカンナビノール
CBN カンナビノール
CBNV カンナビナバリン
CBDA カンナビジオール酸
THCV テトラヒドロカンナビバリン
UGT UDPG‐依存グルコシルトランスフェラーゼ
UDPG ウリジンジホスホグルコース
UDP ウリジン2リン酸
AEA アラキドノイルエタノールアミド(別名アナンダミド)
2‐AG 2‐アラキドノイルエタノールアミド
1‐AG 1‐アラキドノイルエタノールアミド
DHEA N‐ドコサヘキサエノイルエタノールアミン(別名シナプタミド)
SUS スクロースシンターゼ
(式中、Rは、H、β‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;
R’は、H、またはβ‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;かつ
Aは、カンナビノイド化合物、エンドカンナビノイド化合物、もしくはバニロイド化合物、のヒドロキシル基の反応を通して形成されたアグリコン部分構造である。)。
A’は:
であり;
A’’は:
であり;
かつA’’’は:
であり、
Gは、H、β‐D‐グルコピラノシル、3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシル、もしくはβ‐D‐グルコピラノシル‐(1→3)‐β‐D‐グルコピラノシル‐(1→3)‐D‐グルコピラノシルであり;またはそれらの薬学的に適合する塩である。
(式中、Rは、H、β‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;
R’は、H、またはβ‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;かつ
A’は:
であり;
Gは、β‐D‐グルコピラノシル、3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシル、またはβ‐D‐グルコピラノシル‐(1‐3)‐β‐D‐グルコピラノシル‐(1‐3)‐D‐グルコピラノシルである。)。
を含む。
を含む。
を含む。
(式中、Rは、H、β‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;
R’は、H、またはβ‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;かつ
A’’は:
である。)。
を含む。
を含む。
を含む。
を含む。
(式中、Rは、H、β‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;
R’は、H、またはβ‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;かつ
A’’’は:
を含む。
を含む。
を含む。
本発明は、グリコシルトランスフェラーゼをコードする核酸配列を含む核酸を提供する。本発明のグリコシルトランスフェラーゼは、1次、2次、3次グリコシル化、またはそれらの組み合わせをすることができる。ある実施形態においては、グリコシルトランスフェラーゼは、1次、2次、および3次グリコシル化をすることができる。他の実施形態において、グリコシルトランスフェラーゼは、2次、および3次グリコシル化をすることができる。ある実施形態においては、核酸は、UDP‐グルコシルトランスフェラーゼを含むがこれに限定されないグルコシルトランスフェラーゼをコードする。グルコシルトランスフェラーゼは、UGT76G1またはUGT74G1などのステビア レバウディアナのUDP‐グルコシルトランスフェラーゼ、またはOs03g0702000などのイネのグルコシルトランスフェラーゼを含むが、これらに限定されない。他の実施形態において、本発明は、シクロデキストリングルカノトランスフェラーゼをコードするヌクレオチド配列を含む核酸を提供する。スクロースシンターゼをコードするヌクレオチド配列を含む核酸もまた提供する。
MENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYSNWQILKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRVMVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSL
MHHHHHHGSGENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYSNWQILKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRVMVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSL
MHQHQHQSGSMENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYSNWQILKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRVMVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSL
MENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYSNWQILKEILGKMIKQTRASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRVMVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLESLVSYISSLGSHHHHHH
ATGGAAAATAAAACGGAGACCACCGTTCGCCGGCGCCGGAGAATAATATTATTCCCGGTACCATTTCAAGGCCACATTAACCCAATTCTTCAGCTAGCCAATGTGTTGTACTCTAAAGGATTCAGTATCACCATCTTTCACACCAACTTCAACAAACCCAAAACATCTAATTACCCTCACTTCACTTTCAGATTCATCCTCGACAACGACCCACAAGACGAACGCATTTCCAATCTACCGACTCATGGTCCGCTCGCTGGTATGCGGATTCCGATTATCAACGAACACGGAGCTGACGAATTACGACGCGAACTGGAACTGTTGATGTTAGCTTCTGAAGAAGATGAAGAGGTATCGTGTTTAATCACGGATGCTCTTTGGTACTTCGCGCAATCTGTTGCTGACAGTCTTAACCTCCGACGGCTTGTTTTGATGACAAGCAGCTTGTTTAATTTTCATGCACATGTTTCACTTCCTCAGTTTGATGAGCTTGGTTACCTCGATCCTGATGACAAAACCCGTTTGGAAGAACAAGCGAGTGGGTTTCCTATGCTAAAAGTGAAAGACATCAAGTCTGCGTATTCGAACTGGCAAATACTCAAAGAGATATTAGGGAAGATGATAAAACAAACAAGAGCATCTTCAGGAGTCATCTGGAACTCATTTAAGGAACTCGAAGAGTCTGAGCTCGAAACTGTTATCCGTGAGATCCCGGCTCCAAGTTTCTTGATACCACTCCCCAAGCATTTGACAGCCTCTTCCAGCAGCTTACTAGACCACGATCGAACCGTTTTTCAATGGTTAGACCAACAACCGCCAAGTTCGGTACTGTATGTTAGTTTTGGTAGTACTAGTGAAGTGGATGAGAAAGATTTCTTGGAAATAGCTCGTGGGTTGGTTGATAGCAAGCAGTCGTTTTTATGGGTGGTTCGACCTGGGTTTGTCAAGGGTTCGACGTGGGTCGAACCGTTGCCAGATGGGTTCTTGGGTGAAAGAGGACGTATTGTGAAATGGGTTCCACAGCAAGAAGTGCTAGCTCATGGAGCAATAGGCGCATTCTGGACTCATAGCGGATGGAACTCTACGTTGGAAAGCGTTTGTGAAGGTGTTCCTATGATTTTCTCGGATTTTGGGCTCGATCAACCGTTGAATGCTAGATACATGAGTGATGTTTTGAAGGTAGGGGTGTATTTGGAAAATGGGTGGGAAAGAGGAGAGATAGCAAATGCAATAAGAAGAGTTATGGTGGATGAAGAAGGAGAATACATTAGACAGAATGCAAGAGTTTTGAAACAAAAGGCAGATGTTTCTTTGATGAAGGGTGGTTCGTCTTACGAATCATTAGAGTCTCTAGTTTCTTACATTTCATCGTTGTAA
ATGCACCACCATCACCACCATGGTTCTGGTGAAAACAAAACTGAAACTACTGTTAGAAGAAGAAGAAGAATCATTTTGTTTCCAGTACCATTTCAAGGCCATATCAATCCAATTCTTCAATTGGCCAATGTTTTGTACTCCAAAGGATTCTCCATCACCATTTTTCACACCAATTTCAACAAACCAAAGACTTCCAACTATCCTCACTTCACTTTCAGATTTATTTTGGATAATGATCCTCAAGATGAAAGAATTTCCAATCTTCCGACTCATGGTCCTTTGGCTGGTATGAGAATTCCAATCATCAATGAACATGGTGCTGATGAATTAAGAAGAGAATTGGAACTTTTGATGTTGGCTTCTGAAGAAGATGAAGAAGTTTCATGTTTAATCACTGATGCTTTATGGTATTTTGCTCAATCTGTTGCTGATTCTTTGAATTTGCGACGGTTGGTTTTGATGACTTCTTCTTTGTTCAACTTTCATGCTCATGTTTCTTTACCTCAGTTTGATGAACTTGGATATTTGGATCCAGATGACAAAACTAGATTGGAAGAACAAGCTAGTGGGTTTCCTATGTTGAAAGTCAAAGATATCAAATCTGCTTACTCCAACTGGCAAATTCTCAAAGAAATTTTGGGAAAAATGATCAAACAAACAAAAGCTTCTTCTGGAGTCATTTGGAACTCATTCAAAGAATTGGAAGAATCTGAATTGGAAACTGTTATTAGAGAAATTCCTGCTCCAAGTTTTTTGATTCCTTTGCCAAAACATTTGACTGCTTCTTCTTCTTCTTTATTGGATCACGATAGAACTGTTTTTCAATGGTTAGATCAACAACCTCCATCTTCTGTTTTGTATGTTAGTTTTGGATCTACTTCTGAAGTTGATGAAAAAGATTTTTTGGAAATTGCTAGAGGTTTGGTTGATTCCAAACAAAGTTTTTTATGGGTTGTTAGACCAGGATTTGTCAAAGGATCTACTTGGGTCGAACCTTTGCCAGATGGATTTTTGGGAGAAAGAGGAAGAATTGTCAAATGGGTTCCACAGCAAGAAGTTTTGGCTCATGGTGCTATTGGTGCTTTTTGGACTCATTCTGGATGGAACTCTACTTTGGAATCTGTTTGTGAAGGTGTTCCAATGATTTTTTCTGATTTTGGTTTGGATCAACCATTGAATGCTAGATACATGTCTGATGTTTTGAAAGTTGGTGTTTATTTGGAAAATGGGTGGGAAAGAGGTGAAATTGCCAATGCTATTAGAAGAGTCATGGTTGATGAAGAAGGAGAATACATTAGACAAAATGCTAGAGTTTTGAAACAAAAAGCTGATGTTTCTTTGATGAAGGGTGGATCTTCTTATGAATCTTTGGAATCTTTGGTTTCTTACATTTCTTCTCTTTAA
ATGCATCAACATCAACACCAATCTGGATCTATGGAGAACAAGACCGAGACTACAGTTAGAAGAAGAAGAAGAATAATCCTGTTTCCAGTACCATTCCAAGGACACATCAACCCAATCTTGCAGTTAGCAAATGTACTTTATTCTAAAGGCTTTAGTATTACGATTTTTCACACTAATTTTAATAAGCCAAAAACATCCAATTACCCTCACTTCACATTCAGATTTATCTTGGATAACGATCCTCAAGATGAACGTATCTCCAACCTGCCAACACATGGACCATTGGCCGGTATGCGTATTCCTATAATCAACGAGCATGGTGCTGATGAGCTTAGACGTGAACTGGAACTGTTGATGCTGGCATCGGAGGAAGATGAAGAGGTTAGTTGCTTGATAACGGATGCCCTCTGGTATTTCGCACAATCAGTCGCTGACTCCTTGAACCTTAGGAGATTGGTATTGATGACTAGTTCGTTGTTCAACTTCCATGCCCATGTTTCTTTGCCTCAATTTGATGAGCTGGGTTATTTGGATCCTGACGATAAGACTCGTTTAGAAGAACAGGCGTCAGGCTTCCCCATGTTAAAGGTTAAAGATATTAAGTCCGCCTATTCTAACTGGCAAATTCTCAAAGAGATTCTAGGGAAAATGATTAAACAAACCAAGGCCTCTTCAGGAGTAATCTGGAACAGTTTCAAAGAACTAGAAGAATCCGAGTTGGAAACTGTTATTCGTGAAATCCCTGCTCCATCTTTCCTTATCCCATTACCAAAGCACCTCACTGCCTCCTCTAGTTCTCTTCTGGACCATGATAGAACAGTCTTTCAGTGGCTCGATCAGCAACCTCCATCTTCTGTCTTGTACGTTAGTTTTGGTTCCACCTCGGAAGTAGATGAAAAAGACTTTCTGGAAATTGCTCGAGGACTAGTTGACTCCAAGCAATCCTTTCTGTGGGTTGTTAGACCTGGATTCGTAAAAGGATCCACCTGGGTAGAACCCCTCCCAGATGGATTTTTGGGCGAAAGGGGAAGAATTGTTAAATGGGTGCCTCAACAAGAAGTTTTAGCTCATGGGGCCATTGGAGCTTTTTGGACTCATAGTGGATGGAATTCTACCTTAGAATCTGTTTGTGAAGGAGTTCCAATGATTTTTTCTGATTTTGGATTGGATCAGCCTCTTAATGCCAGATATATGTCCGATGTCCTCAAGGTCGGAGTGTACCTGGAAAATGGTTGGGAGAGAGGTGAGATTGCAAATGCTATACGTAGAGTCATGGTTGATGAAGAGGGCGAGTATATTAGACAAAACGCTAGAGTGCTAAAGCAGAAGGCCGATGTTTCCCTTATGAAGGGGGGAAGTTCATATGAGAGTTTGGAATCCCTAGTGTCCTACATTTCTTCGCTATAA
ATGGAAAATAAAACCGAAACCACCGTCCGTCGCCGTCGTCGTATCATTCTGTTCCCGGTCCCGTTCCAAGGTCACATCAACCCGATTCTGCAGCTGGCCAACGTGCTGTATAGCAAAGGTTTCTCTATCACCATCTTCCATACGAACTTCAACAAACCGAAAACCTCTAACTACCCGCACTTTACGTTCCGTTTTATTCTGGATAACGACCCGCAGGATGAACGCATCAGTAATCTGCCGACCCATGGTCCGCTGGCGGGTATGCGTATTCCGATTATCAACGAACACGGCGCAGATGAACTGCGTCGCGAACTGGAACTGCTGATGCTGGCCTCTGAAGAAGATGAAGAAGTTAGTTGCCTGATCACCGACGCACTGTGGTATTTTGCCCAGAGTGTTGCAGATTCCCTGAACCTGCGTCGCCTGGTCCTGATGACGAGCTCTCTGTTCAATTTTCATGCCCACGTTTCCCTGCCGCAGTTCGATGAACTGGGTTATCTGGACCCGGATGACAAAACCCGCCTGGAAGAACAAGCTTCAGGCTTTCCGATGCTGAAAGTCAAAGATATTAAAAGTGCGTACTCCAACTGGCAGATTCTGAAAGAAATCCTGGGTAAAATGATCAAACAAACCCGTGCAAGTTCCGGCGTCATCTGGAATTCCTTCAAAGAACTGGAAGAATCAGAACTGGAAACGGTGATTCGCGAAATCCCGGCTCCGTCTTTTCTGATTCCGCTGCCGAAACATCTGACCGCGTCATCGAGCTCTCTGCTGGATCACGACCGTACGGTGTTTCAGTGGCTGGATCAGCAACCGCCGAGTTCCGTGCTGTACGTTAGCTTCGGTAGCACCTCTGAAGTGGATGAAAAAGACTTTCTGGAAATCGCTCGTGGCCTGGTTGATTCAAAACAATCGTTCCTGTGGGTGGTTCGCCCGGGTTTTGTGAAAGGCAGCACGTGGGTTGAACCGCTGCCGGATGGCTTCCTGGGTGAACGTGGTCGCATTGTCAAATGGGTGCCGCAGCAAGAAGTGCTGGCACATGGTGCTATCGGCGCGTTTTGGACCCACTCAGGTTGGAACTCGACGCTGGAAAGCGTTTGTGAAGGTGTCCCGATGATTTTCTCGGATTTTGGCCTGGACCAGCCGCTGAATGCACGTTATATGAGCGATGTTCTGAAAGTCGGTGTGTACCTGGAAAACGGTTGGGAACGCGGCGAAATTGCGAATGCCATCCGTCGCGTTATGGTCGATGAAGAAGGCGAATATATCCGTCAGAATGCTCGCGTCCTGAAACAAAAAGCGGACGTTAGTCTGATGAAAGGCGGTTCATCGTACGAATCCCTGGAATCACTGGTCTCCTACATTTCTTCTCTGGGCTCGCATCATCATCATCATCATTAA
MENKTETTVRRRRRIILFPVPVQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDVRISNLPTHGPLTVMRILIINEHGADELQRELELLMLASEEDGEVSCLITDQIWYFTQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKCGFSMWKQGKEIFENITKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFPWLDQQPSRSVLYVSFGSATEVDAKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSAFAFDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRVMVDEEGGYIRQNASVLKQKADVSLMKGGSSYESLESLVAYISSL
ATGGAAAATAAAACGGAGACCACCGTTCGCCGGCGCCGGAGAATAATATTATTCCCGGTACCAGTTCAAGGCCACATTAACCCAATTCTTCAGCTAGCCAATGTGTTGTACTCCAAAGGATTCAGTATCACCATCTTTCACACCAACTTCAACAAACCCAAAACATCTAATTACCCTCACTTCACTTTCAGATTCATCCTCGACAACGACCCACAAGACGTACGCATTTCCAATCTACCGACTCATGGTCCGCTCACTGTTATGCGGATTCTGATTATCAACGAACACGGAGCTGACGAATTACAACGCGAACTGGAACTGTTGATGTTAGCTTCTGAAGAAGATGGAGAGGTATCGTGTTTAATCACCGATCAGATTTGGTACTTCACGCAATCTGTTGCTGACAGTCTTAACCTCCGACGGCTTGTTTTGATGACAAGCAGCTTGTTTAATTTTCATGCACATGTTTCACTTCCTCAGTTTGATGAGCTTGGTTACCTCGATCCTGATGACAAAACCCGTTTGGAAGAACAAGCGAGTGGGTTTCCTATGCTGAAAGTGAAAGATATCAAGTGTGGTTTTTCGATGTGGAAACAAGGCAAAGAGATATTCGAGAACATTACGAAACAAACAAAAGCATCTTCAGGAGTCATCTGGAACTCATTTAAGGAACTCGAAGAGTCTGAGCTCGAAACTGTTATCCGTGAGATCCCGGCTCCAAGTTTCTTGATACCACTCCCCAAGCATTTGACAGCCTCTTCCAGCAGCTTACTAGACCACGATCGAACCGTTTTTCCATGGTTAGACCAACAACCGTCACGTTCGGTACTGTATGTTAGTTTTGGTAGTGCTACTGAAGTGGATGCGAAAGATTTCTTGGAAATAGCTCGTGGGTTGGTTGATAGCAAGCAGTCGTTTTTATGGGTGGTTCGACCTGGTTTTGTCAAGGGTTCGACGTGGGTCGAACCGTTGCCAGATGGGTTCTTGGGTGAAAGAGGACGTATTGTGAAATGGGTTCCGCAGCAAGAAGTGCTAGCTCATGGAGCAATAGGCGCATTCTGGACTCATAGCGGATGGAACTCTACGTTGGAAAGCGTTTGTGAAGGTGTTCCTATGATTTTCTCGGCTTTTGCGTTCGATCAACCGTTGAATGCTAGATACATGAGTGATGTTTTGAAGGTAGGGGTGTATTTGGAAAATGGGTGGGAAAGAGGAGAGATAGCAAATGCAATAAGAAGAGTTATGGTGGATGAAGAAGGAGGATACATTAGACAGAATGCAAGTGTTTTGAAACAAAAGGCAGATGTTTCTTTGATGAAGGGTGGTTCGTCTTACGAATCATTAGAGTCTCTAGTTGCTTACATTTCATCGTTGTAA
MLQLATYLHSQGISITIAQYPNFNSPDSSNHPELTFLPLSSGNLSVADISGGFFKFIQTLNHNCKPHFREYLVQNMSSDDKESIVIIRDNLMFFAGEIAGELGLPSIILRGSNAVMLTASDIIPQLHQEGRFPPPDSLLQETIPELVPFRYKDLPFIGYPIHQTLEFSITMMTPKSPASAILINTLEFLEQSALTQIRDHYKVPVFTIGPLHKIVTTRSTSILEEDTSCINWLDKQSPKSVVYVSLGSLAKLDEKVASEMACGLAMSNHKFLWVVRPGMVHGFEWVEFLPDSLVGEMKARGLIVKWAPQTTVLAHNAVGGFWSHCGWNSTIECLAEGVPMMCQPFFADQLLNARYVSDVWKTGFEIVIEKGEIACAIKRVLVDEEGEEMRQRAMEIKEKVKIAINDGGSSYDSFKDLVAFISSL
ATGCTTCAGCTTGCAACTTACCTCCATTCTCAAGGGATTTCAATAACCATCGCTCAGTACCCCAACTTCAACTCGCCGGATTCTTCCAACCATCCAGAACTAACCTTCCTCCCACTATCCTCCGGCAACTTATCCGTCGCCGACATCTCCGGCGGCTTTTTCAAGTTCATCCAAACTCTTAACCATAACTGCAAACCCCATTTCCGGGAATACCTTGTTCAGAACATGAGTTCTGATGATAAGGAATCAATCGTTATCATCCGTGATAATCTCATGTTTTTCGCCGGAGAAATCGCCGGCGAGCTGGGTCTGCCTTCGATCATTTTACGTGGCAGCAATGCTGTCATGTTGACTGCTAGCGACATCATCCCTCAACTTCATCAAGAAGGTCGTTTTCCGCCACCAGATTCTTTGTTGCAGGAAACAATTCCAGAACTGGTTCCATTCAGATACAAAGATCTACCATTTATTGGCTATCCAATACATCAAACCCTTGAATTTAGTATCACCATGATGACCCCCAAATCACCTGCTTCCGCCATTCTTATCAACACCCTCGAATTTCTTGAACAATCGGCATTAACCCAGATCCGTGATCATTACAAAGTTCCAGTTTTTACAATCGGACCATTGCACAAAATAGTCACAACTCGTTCCACTAGCATTCTTGAAGAAGATACAAGTTGCATCAATTGGTTAGATAAACAATCACCCAAATCAGTGGTTTATGTGAGTTTAGGAAGCTTAGCAAAGTTGGATGAAAAGGTTGCATCTGAAATGGCATGTGGTTTAGCCATGAGTAACCATAAGTTCCTATGGGTGGTTCGACCCGGTATGGTTCATGGGTTTGAATGGGTCGAGTTTTTGCCGGATAGTTTGGTGGGTGAAATGAAGGCTAGAGGTTTGATTGTGAAATGGGCACCCCAGACGACGGTTTTGGCGCATAACGCGGTTGGTGGATTTTGGAGTCATTGCGGTTGGAACTCGACCATAGAATGCTTAGCTGAAGGGGTCCCGATGATGTGTCAACCGTTTTTTGCTGATCAGTTGTTGAATGCTAGGTATGTGAGTGATGTTTGGAAGACGGGTTTTGAGATTGTTATCGAGAAAGGTGAGATTGCGTGCGCGATTAAACGAGTTTTGGTGGATGAAGAAGGCGAAGAAATGAGGCAGAGAGCTATGGAGATTAAAGAAAAGGTTAAAATTGCAATCAACGATGGTGGTTCTTCTTATGACTCGTTCAAGGACTTGGTGGCGTTTATTTCATCACTCTAA
MHQHQHQSGSMDSGYSSSYAAAAGMHVVICPWLAFGHLLPCLDLAQRLASRGHRVSFVSTPRNISRLPPVRPALAPLVAFVALPLPRVEGLPDGAESTNDVPHDRPDMVELHRRAFDGLAAPFSEFLGTACADWVIVDVFHHWAAAAALEHKVPCAMMLLGSAHMIASIADRRLERAETESPAAAGQGRPAAAPTFEVARMKLIRTKGSSGMSLAERFSLTLSRSSLVVGRSCVEFEPETVPLLSTLRGKPITFLGLMPPLHEGRREDGEDATVRWLDAQPAKSVVYVALGSEVPLGVEKVHELALGLELAGTRFLWALRKPTGVSDADLLPAGFEERTRGRGVVATRWVPQMSILAHAAVGAFLTHCGWNSTIEGLMFGHPLIMLPIFGDQGPNARLIEAKNAGLQVARNDGDGSFDREGVAAAIRAVAVEEESSKVFQAKAKKLQEIVADMACHERYIDGFIQQLRSYKD
ATGCATCAGCACCAACATCAGAGCGGTTCTATGGACTCCGGCTACTCCTCCTCCTACGCCGCCGCCGCCGGGATGCACGTCGTGATCTGCCCGTGGCTCGCCTTCGGCCACCTGCTCCCGTGCCTCGACCTCGCCCAGCGCCTCGCGTCGCGGGGCCACCGCGTGTCGTTCGTCTCCACGCCGCGGAACATATCCCGCCTCCCGCCGGTGCGCCCCGCGCTCGCGCCGCTCGTCGCCTTCGTGGCGCTGCCGCTCCCGCGCGTCGAGGGGCTCCCCGACGGCGCCGAGTCCACCAACGACGTCCCCCACGACAGGCCGGACATGGTCGAGCTCCACCGGAGGGCCTTCGACGGGCTCGCCGCGCCCTTCTCGGAGTTCTTGGGCACCGCGTGCGCCGACTGGGTCATCGTCGACGTCTTCCACCACTGGGCCGCAGCCGCCGCTCTCGAGCACAAGGTGCCATGTGCAATGATGTTGTTGGGCTCTGCACATATGATCGCTTCCATAGCAGACAGACGGCTCGAGCGCGCGGAGACAGAGTCGCCTGCGGCTGCCGGGCAGGGACGCCCAGCGGCGGCGCCAACGTTCGAGGTGGCGAGGATGAAGTTGATACGAACCAAAGGCTCATCGGGAATGTCCCTCGCCGAGCGCTTCTCCTTGACGCTCTCGAGGAGCAGCCTCGTCGTCGGGCGGAGCTGCGTGGAGTTCGAGCCGGAGACCGTCCCGCTCCTGTCGACGCTCCGCGGTAAGCCTATTACCTTCCTTGGCCTTATGCCGCCGTTGCATGAAGGCCGCCGCGAGGACGGCGAGGATGCCACCGTCCGCTGGCTCGACGCGCAGCCGGCCAAGTCCGTCGTGTACGTCGCGCTAGGCAGCGAGGTGCCACTGGGAGTGGAGAAGGTCCACGAGCTCGCGCTCGGGCTGGAGCTCGCCGGGACGCGCTTCCTCTGGGCTCTTAGGAAGCCCACTGGCGTCTCCGACGCCGACCTCCTCCCCGCCGGCTTCGAGGAGCGCACGCGCGGCCGCGGCGTCGTGGCGACGAGATGGGTTCCTCAGATGAGCATACTGGCGCACGCCGCCGTGGGCGCGTTCCTGACCCACTGCGGCTGGAACTCGACCATCGAGGGGCTCATGTTCGGCCACCCGCTTATCATGCTGCCGATCTTCGGCGACCAGGGACCGAACGCGCGGCTAATCGAGGCGAAGAACGCCGGATTGCAGGTGGCAAGAAACGACGGCGATGGATCGTTCGACCGAGAAGGCGTCGCGGCGGCGATTCGTGCAGTCGCGGTGGAGGAAGAAAGCAGCAAAGTGTTTCAAGCCAAAGCCAAGAAGCTGCAGGAGATCGTCGCGGACATGGCCTGCCATGAGAGGTACATCGACGGATTCATTCAGCAATTGAGATCTTACAAGGATTGA
MYNVTYHQNSKAMATSDSIVDDRKQLHVATFPWLAFGHILPFLQLSKLIAEKGHKVSFLSTTRNIQRLSSHISPLINVVQLTLPRVQELPEDAEATTDVHPEDIQYLKKAVDGLQPEVTRFLEQHSPDWIIYDFTHYWLPSIAASLGISRAYFCVITPWTIAYLAPSSDAMINDSDGRTTVEDLTTPPKWFPFPTKVCWRKHDLARMEPYEAPGISDGYRMGMVFKGSDCLLFKCYHEFGTQWLPLLETLHQVPVVPVGLLPPEIPGDEKDETWVSIKKWLDGKQKGSVVYVALGSEALVSQTEVVELALGLELSGLPFVWAYRKPKGPAKSDSVELPDGFVERTRDRGLVWTSWAPQLRILSHESVCGFLTHCGSGSIVEGLMFGHPLIMLPIFCDQPLNARLLEDKQVGIEIPRNEEDGCLTKESVARSLRSVVVENEGEIYKANARALSKIYNDTKVEKEYVSQFVDYLEKNARAVAIDHES
ATGTACAACGTTACTTATCATCAAAATTCAAAAGCAATGGCTACCAGTGACTCCATAGTTGACGACCGTAAGCAGCTTCATGTTGCGACGTTCCCATGGCTTGCTTTCGGTCACATCCTCCCTTTCCTTCAGCTTTCGAAATTGATAGCTGAAAAGGGTCACAAAGTCTCGTTTCTTTCTACCACCAGAAACATTCAACGTCTCTCTTCTCATATCTCGCCACTCATAAATGTTGTTCAACTCACACTTCCACGTGTCCAAGAGCTGCCGGAGGATGCAGAGGCGACCACTGACGTCCACCCTGAAGATATTCAATATCTCAAGAAGGCTGTTGATGGTCTTCAACCGGAGGTCACCCGGTTTCTAGAACAACACTCTCCGGACTGGATTATTTATGATTTTACTCACTACTGGTTGCCATCCATCGCGGCTAGCCTCGGTATCTCACGAGCCTACTTCTGCGTCATCACTCCATGGACCATTGCTTATTTGGCACCCTCATCTGACGCCATGATAAATGATTCAGATGGTCGAACCACGGTTGAGGATCTCACGACACCGCCCAAGTGGTTTCCCTTTCCGACCAAAGTATGCTGGCGGAAGCATGATCTTGCCCGAATGGAGCCTTACGAAGCTCCGGGGATATCTGATGGATACCGTATGGGGATGGTTTTTAAGGGATCTGATTGTTTGCTTTTCAAATGTTACCATGAGTTTGGAACTCAATGGCTACCTCTTTTGGAGACACTACACCAAGTACCGGTGGTTCCGGTGGGATTACTGCCGCCGGAAATACCCGGAGACGAGAAAGATGAAACATGGGTGTCAATCAAGAAATGGCTCGATGGTAAACAAAAAGGCAGTGTGGTGTACGTTGCATTAGGAAGCGAGGCTTTGGTGAGCCAAACCGAGGTTGTTGAGTTAGCATTGGGTCTCGAGCTTTCTGGGTTGCCATTTGTTTGGGCTTATAGAAAACCAAAAGGTCCCGCGAAGTCAGACTCGGTGGAGTTGCCAGACGGGTTCGTGGAACGAACTCGTGACCGTGGGTTGGTCTGGACGAGTTGGGCACCTCAGTTACGAATACTGAGCCACGAGTCAGTTTGTGGTTTCTTGACTCATTGTGGTTCTGGATCAATTGTGGAAGGGCTAATGTTTGGTCACCCTCTAATCATGCTACCGATTTTTTGTGACCAACCTCTGAATGCTCGATTACTGGAGGACAAACAGGTGGGAATCGAGATACCAAGAAATGAGGAAGATGGTTGCTTGACCAAGGAGTCGGTTGCTAGATCACTGAGGTCCGTTGTTGTGGAAAACGAAGGGGAGATCTACAAGGCGAACGCGAGGGCGCTGAGTAAAATCTATAACGACACTAAGGTGGAAAAAGAATATGTAAGCCAATTCGTAGACTATTTGGAAAAGAATGCGCGTGCGGTTGCCATCGATCATGAGAGTTAA
MATSDSIVDDRKQLHVATFPWLAFGHILPYLQLSKLIAEKGHKVSFLSTTRNIQRLSSHISPLINVVQLTLPRVQELPEDAEATTDVHPEDIPYLKKASDGLQPEVTRFLEQHSPDWIIYDYTHYWLPSIAASLGISRAHFSVTTPWAIAYMGPSADAMINGSDGRTTVEDLTTPPKWFPFPTKVCWRKHDLARLVPYKAPGISDGYRMGLVLKGSDCLLSKCYHEFGTQWLPLLETLHQVPVVPVGLLPPEIPGDEKDETWVSIKKWLDGKQKGSVVYVALGSEVLVSQTEVVELALGLELSGLPFVWAYRKPKGPAKSDSVELPDGFVERTRDRGLVWTSWAPQLRILSHESVCGFLTHCGSGSIVEGLMFGHPLIMLPIFGDQPLNARLLEDKQVGIEIPRNEEDGCLTKESVARSLRSVVVEKEGEIYKANARELSKIYNDTKVEKEYVSQFVDYLEKNARAVAIDHES
ATGGCCACATCTGACTCTATCGTTGATGACAGAAAACAATTGCATGTTGCTACTTTCCCATGGTTGGCCTTTGGACACATTCTGCCCTACTTGCAATTGTCAAAGCTGATTGCAGAAAAAGGTCATAAGGTGTCCTTTTTGTCTACCACAAGAAACATCCAGAGACTAAGTTCTCATATTTCTCCATTGATTAATGTGGTTCAGTTGACCTTGCCTAGAGTCCAAGAACTTCCCGAAGACGCAGAAGCTACTACTGATGTTCACCCTGAAGATATCCCATATCTAAAGAAGGCATCTGATGGACTTCAACCAGAAGTAACCAGGTTTTTGGAGCAGCACAGTCCTGACTGGATTATCTATGATTATACTCATTACTGGCTTCCATCCATCGCAGCTAGTCTAGGCATTTCCAGAGCTCATTTCTCTGTCACTACCCCATGGGCAATTGCATATATGGGTCCTTCTGCTGATGCAATGATCAACGGTTCTGATGGTAGGACCACTGTTGAAGATTTAACTACACCTCCAAAGTGGTTCCCATTTCCTACTAAAGTTTGTTGGCGAAAACACGATCTGGCACGTTTGGTCCCATATAAGGCTCCAGGTATCTCCGATGGATATCGAATGGGTCTGGTGCTAAAGGGTTCTGATTGTCTGTTATCTAAGTGTTACCACGAATTTGGAACTCAATGGCTTCCTCTATTAGAGACTCTGCATCAAGTTCCAGTTGTTCCTGTCGGTCTGCTACCACCTGAAATTCCCGGTGACGAAAAGGACGAAACTTGGGTTTCCATAAAAAAATGGCTGGATGGTAAGCAGAAGGGTAGTGTTGTATATGTCGCTTTAGGCTCCGAGGTTTTGGTATCCCAGACTGAAGTTGTGGAACTTGCCTTAGGATTGGAGTTGTCCGGTTTGCCATTCGTCTGGGCATATAGAAAGCCAAAGGGACCAGCTAAGTCAGACTCAGTTGAATTGCCAGATGGTTTCGTAGAAAGGACAAGAGACAGAGGATTGGTTTGGACATCATGGGCCCCACAATTGAGAATTCTGAGTCATGAAAGTGTGTGTGGATTCTTGACTCACTGTGGCTCTGGCAGTATTGTTGAAGGACTGATGTTTGGACACCCACTGATAATGTTGCCAATCTTCGGTGACCAACCTCTGAATGCAAGATTGCTGGAGGATAAACAAGTTGGTATCGAAATCCCAAGAAACGAGGAAGACGGCTGCCTGACTAAGGAATCAGTTGCACGTAGTTTAAGATCTGTAGTTGTTGAAAAAGAAGGTGAAATATATAAGGCTAACGCTAGAGAACTTTCAAAGATATACAATGATACCAAGGTGGAGAAAGAATATGTTTCACAGTTTGTGGACTATTTGGAGAAAAACGCTAGAGCCGTTGCTATCGATCACGAATCATAG
MAEQQKIKKSPHVLLIPFPLQGHINPFIQFGKRLISKGVKTTLVTTIHTLNSTLNHSNTTTTSIEIQAISDGCDEGGFMSAGESYLETFKQVGSKSLADLIKKLQSEGTTIDAIIYDSMTEWVLDVAIEFGIDGGSFFTQACVVNSLYYHVHKGLISLPLGETVSVPGFPVLQRWETPLILQNHEQIQSPWSQMLFGQFANIDQARWVFTNSFYKLEEEVIEWTRKIWNLKVIGPTLPSMYLDKRLDDDKDNGFNLYKANHHECMNWLDDKPKESVVYVAFGSLVKHGPEQVEEITRALIDSDVNFLWVIKHKEEGKLPENLSEVIKTGKGLIVAWCKQLDVLAHESVGCFVTHCGFNSTLEAISLGVPVVAMPQFSDQTTNAKLLDEILGVGVRVKADENGIVRRGNLASCIKMIMEEERGVIIRKNAVKWKDLAKVAVHEGGSSDNDIVEFVSELIKA
ATGGCGGAACAACAAAAGATCAAGAAATCACCACACGTTCTACTCATCCCATTCCCTTTACAAGGCCATATAAACCCTTTCATCCAGTTTGGCAAACGATTAATCTCCAAAGGTGTCAAAACAACACTTGTTACCACCATCCACACCTTAAACTCAACCCTAAACCACAGTAACACCACCACCACCTCCATCGAAATCCAAGCAATTTCCGATGGTTGTGATGAAGGCGGTTTTATGAGTGCAGGAGAATCATATTTGGAAACATTCAAACAAGTTGGGTCTAAATCACTAGCTGACTTAATCAAGAAGCTTCAAAGTGAAGGAACCACAATTGATGCAATCATTTATGATTCTATGACTGAATGGGTTTTAGATGTTGCAATTGAGTTTGGAATCGATGGTGGTTCGTTTTTCACTCAAGCTTGTGTTGTAAACAGCTTATATTATCATGTTCATAAGGGTTTGATTTCTTTGCCATTGGGTGAAACTGTTTCGGTTCCTGGATTTCCAGTGCTTCAACGGTGGGAGACACCGTTAATTTTGCAGAATCATGAGCAAATACAGAGCCCTTGGTCTCAGATGTTGTTTGGTCAGTTTGCTAATATTGATCAAGCACGTTGGGTCTTCACAAATAGTTTTTACAAGCTCGAGGAAGAGGTAATAGAGTGGACGAGAAAGATATGGAACTTGAAGGTAATCGGGCCAACACTTCCATCCATGTACCTTGACAAACGACTTGATGATGATAAAGATAACGGATTTAATCTCTACAAAGCAAACCATCATGAGTGCATGAACTGGTTAGACGATAAGCCAAAGGAATCAGTTGTTTACGTAGCATTTGGTAGCCTGGTGAAACATGGACCCGAACAAGTGGAAGAAATCACACGGGCTTTAATAGATAGTGATGTCAACTTCTTGTGGGTTATCAAACATAAAGAAGAGGGAAAGCTCCCAGAAAATCTTTCGGAAGTAATAAAAACCGGAAAGGGTTTGATTGTAGCATGGTGCAAACAATTGGATGTGTTAGCACACGAATCAGTAGGATGCTTTGTTACACATTGTGGGTTCAACTCAACTCTTGAAGCAATAAGTCTTGGAGTCCCCGTTGTTGCAATGCCTCAATTTTCGGATCAAACTACAAATGCCAAGCTTCTAGATGAAATTTTGGGTGTTGGAGTTAGAGTTAAGGCTGATGAGAATGGGATAGTGAGAAGAGGAAATCTTGCGTCATGTATTAAGATGATTATGGAGGAGGAAAGAGGAGTAATAATCCGAAAGAATGCGGTAAAATGGAAGGATTTGGCTAAAGTAGCCGTTCATGAAGGTGGTAGCTCAGACAATGATATTGTCGAATTTGTAAGTGAGCTAATTAAGGCTTAA
MAERVLTRVHSLRERLDSTLATHRNEILLFLSRIESHGKGILKPHQVMTEFEAICKEDQSKLSDGAFYEVLKCTQEAIVQPPWVALAIRLRPGVWEYVRVNVNVLVVEELSVPEYLHFKEELVNGTSNGNFVLELDFEPFTASFPRPTLTKSIGNGVEFLNRHLSAKMFHDKDSMHPLLDFLRTHHYKGKTMMLNDRIQNLNALQSVLRKASEYLSTLDAATPYSEFEHKFQEIGLERGWGDKAEVVMEMIHMLLDLLEAPDACTLEKFLGRIPMVFNVVILSPHGYFAQENVLGYPDTGGQVVYILDQVPALEREMLKRIKEQGLDIIPRILIVTRLLPDAVGTTCGQRLEKVFGAEHSHILRVPFRTEKGILRKWISRFEVWPYIETFTEDVAKEVTAELQAKPDLIIGNYSEGNLVASLLAHKLGVTQCTIAHALEKTKYPDSDIYWKNFEEKYHFSSQFTADLIAMNHTDFIITSTFQEIAGSKDTVGQYESHTAFTMPGLYRVVHGIDVFDPKFNIVSPGADMGIYYSYTEKEKRLTALHPEIDELLFSSVENEEHLCVLKDKSKPILFTMARLDNVKNLTGLVEWYAKNDRLRELVNLVVVGGDRRKESKDLEEQAQMQKMHELIETYKLNGQFRWISSQMNRVRNGELYRVIADTRGAFIQPAFYEAFGLTVVEAMTCGLPTFATLHGGPAEIIVHGKSGFHIDPYHGDQVTELLVNFFEKTKQDPGHWEAISKGGLQRIQEKYTWQIYSDRLLTLAGVYGFWKHVSKLDRLEIRRYLEMFYALKYRKLAESVPLAVDE
MATSKLSRTHSMRERVEETLSAHRNEIVSLLSRYVAQGKAILQPHQILHELENIIGDVTSRQKLTDGPFGDALKTAQECIVLPPFVALAVRPRPGVWEYVRVDAYQLSVEQLTVSEYLTFKEELVGESNSSLMLELDFEPFNASFPRPTRSSSIGNGVQFLNRHLSSSMFRSKDCLEPLLDFLRTHRHNGHVMMLNDRITSMTRLQSSLVKAEEYLSKLPSDTDYSEFQYELQGMGFERGWGNNAERIIEMMHLLSDILQAPDPSILESFLARIPMVFNVVILSIHGYFGQANVLGLPDTGGQIVYILDQVRALENEMLLKLKHQGLDIKPRILIVTRLIPDAKGTSCNQRLERVSGTEHTHILRVPFRTEKGILRKWISRFDVWPFLEKFTQDAASEISAELHGTPDLIIGNYSDGNLVASLLSYKMGVTQCNIAHALEKTKYPDSDLYWKKFDEKYHFSCQFTADLLAMNNADFIITSTYQEIAGTKNTVGQYESHSSFTLPGLYRVVHGIDVFDPKFNIVSPGADMSIYFSYTEKEKRLTSLHTTIEKLLFDPTQTEDYIGNLSDKSKPIIFSMARLDHVKNITGLVEWYAKNEKLRGLANLVVVAGYNNVKRSSDREEIAEIEKMHQLIKKYKLDGQMRWISAQTNRAQNGELYRYIADGRGIFVQPAIYEAFGLTVVEAMTCGLPTFATCHGGPGEIIENGVSGFHIDPYHPDTASATMADFFQKCKEDPSYWFKISEAGLKRIYERYTWKIYSERLMTLAGVYSFWKYVSKLERRETRRYLEMFYILKFRDLVKSVPVATDDEA
MATPKLTRTPSMRERLEETLSAHRNDIVSLLSRYVDQGKAILQPHHLLDEIDNFIGDQNCRQKLADSLFGEILKSAQEGIILPPYVTLAVRPRPGVWDFLRVNVDELSVEQLTVSEYLSFKEELVDGQSRNPFVLELDLEPFNATFPRMSRSSSIGNGVQFLNRHLSSIMFRNKDCMDPFLDFLRAHKHKGYAMMLNDRIQTMSRLESSLAKAEDHLSKLPPETPYSEFEYVLQGMGFERGWGDNCERVLGMMHLLSDILQAPDPSILEKFLGKMPMIFNVVVLSIHGYFGQANVLGLPDTGGQVVYILDQVRSLENEMLLKLRHQGLDIKPKILIVTRLIPNAKGTSCNQRLEKVSGTEYTYILRVPFRTEKGILGKWLSRFDIWPYLEAFTTDAASEIAAELHGVPDLLIGNYSDGNLVASLLSNKLGVTQCNIAHALEKTKYPDSDLYWKKFEDKYHFSCQFTADLLAMNNADFIITSTYQEIAGTKNTVGQYENHSSFTLPGLYRVVHGIDVFDPKFNIVSPGADMAIYFSYADKERRLTSLHPTIEKLLFDTEQNDVHIGNINDPSKPMIFTMARLDHVKNITGFVECYAKNNKLREHANLVVIAGYNDAKKSSDREEIAEIEKMHNLIKQYKLDGQMRWISAQTNRARNGEFYRYIADGRGVFVQPAFYEAFGLTVVEAMTCGLPTFATCHGGPAEIIEDGVSGFHIDPYHPDKMSTTLADFFQKCKEEPSYWGKISDGGLKRISERYTWKIYSERLMTLAGVYSFWKYVSKLERRETRRYLEMFYILKFRQLVKSVPLAVDEEP
MASASSSIMKRSESIVDTMPEALKQSRYHMKKCFLKYVEKGIRMMKRHHLIQEMETAIEDKDEKAQLLDGLLGYILCTTQEAAVVPPCVAFAIRPNPGFWEFVKVNSNDLSVDGITATDYLKFKEMIVDETWAKDENALEIDFGSMDFNLPNMSLSCSIGNGVNFTSKFITCKLYAQSSCQQLLVDYLLSLNHQGENLMINDALNSVSKLRAALIVAHASLSSLPNDTPYQSFELRFKEWGFEKGWGDNAERARETIRFLLEVLQAPDPINLEALFSRIPNIFNVVLFSIHGYFGQSNVLGLPDTGGQVVYVLDQVVAMEEELLMRIKQQGLNFKPQILVVTRLLPDAKGTKCNQVLEPVLNTKHSHILRVPFRTDKGVLRKWVSRFDIYPYLENFTQDASAKIIEMMEGKPDLIIGNYTDGNLVASLMANKLGTTLGTIAHALEKTKYEDSDMNWKQFDPKYHFSCQFTADMIAMNSADFIITSTFQEIAGSKDRPGQYESHEAFTLPGLYRVVSGINVFDPKFNIASPGADQTVYFPYTETKKRFTAFQPAIEELLFSKVENEEHIGYLEDKTKPIIFSMARLDTVKNITGLTEWFGENKRLRSLVNLVIVAGFFDPSKSKDREEMAEIKKMHLLIEKYQLKGQIRWIAAQTDKNRNSELYRFIADSKGAFVQPALYEAFGLTVIEAMNCGLPTFATNQGGPAEIIVDGVSGFQIDPNFGDQSSNKIADFFQKCKEDPGYWNNISEGGLKRIYECYTWKIYANKVLNMGNIYSFWKRLNKEQKEAKQRYIELFYNLHYKNLVRTVPIASDEAQPAPVSRAKLATQPTRRTQSRLQRLFGA
MAASSSPIMKRSESVLDTMPEALRQSRYHMKKCFLKYVGKGKRMVKLHHLMQEMETVIEDKDEKAQLLEGLLGYILCTTQEAAVVPPYVAFAIRPNPGFWEFVKVNSNDLSVKGITSTDYLKFKEMIVDETWANDENALEIDFGAMDFNLPTMSLSSSIGNGVNFTSKFIISKLYAHSGSQLQSLVDYLLSLNHQGEKLMINDKLNTVSKLQAALIVAHSFLSSLPNDTPYQSFELRFKEWGFEKGWGDYAERVQETIRFLLEVLQAPDPVNLEAFFSRVPNIFNIVLFSIHGYFGQSNVLGLPDTGGQVVYVLDQVVAMEEELLLRIKQQGLSFKPHILVVTRLLPDAKGTECSQVLEPVLNTKHSHILRVPFRTEKGVLRKWVSRFDIYPYLEKFTQDASAKITEMMEGKPDLIIGNYTDGNLVASLMANKLGSTLGTIAHALEKTKYEDSDMKWKHLDTKYHFSCQFTADMIAMNSADFIITSTFQEIAGSKDRPGQYESHEAFTLPGLYRVVSGINVFDPKFNIASPGADQTVYFPYTETPKRFTTFQPAIQELLFSKVENDEHIGYLEDKNKPIIFSMARLDMVKNITGLTEWFGENKRLRSLVNLVIVAGFFDPSKSKDREEMEEIKKMHLLIEKYELKGQIRWIVAQTDKNRNSELYRCIADSKGAFVQPALYEAFGLTVIEAMNCGLPTFATNQGGPAEIIVDGVSGFQIDPNYGDESSNKIADFFQKCKQDPGYWNRISDGGLMRIYECYTWKIYANKVLNMGNIYTFWKQLNKEQKDAKQRYIELFYNQHYKNLVRTVPIVSDEDDQVTRAKPATQPSTRRTQSALQRLLGA
MDFGIAETLAEALKQNRYHARRCFERFTSRGKRMVKPQELLHMIEKTIDDKLERTKVLEGSMGQILSSTQEAIVIPPYVILGLRANPGQWAYVKINADDVTVESLTPSQYLKFKESIYDQEWAKDENALELDFGAFDFDTPRLILPSSIGNGLGYISKFMTSRIGGDLENAKPLLDHLLALKYHGEKLMINETIDTVSKLQKALIVADVYLSAHPKDEQYQTLEPKLKEWGFEKGWGDTAERVRETMKMLSEILQAPDPINMQSFFSRLPVVFNIVIFSIHGYFGQSDVLGLPDTGGQVVYILDQVKALEEEILLRIKMQGLNAKPRILVVSRLIPDAQGTKCNEEMEPILNTMHSHILRVPFRTSKGVVPQWVSRFDIYPYLERFSQDAASKILEVMECKPDLILGNYTDGNIVASLIAKKFGVTQGTIAHALEKTKYEDSDVNWKNFEKKYHFSCQFTADLISMNAADFIITSTYQEIVGSKQRPGQYETHGAFSMPGLCRVVSGINVFDPKFNIASPGAEQSVYFPYTEKEKRLTDFHPAIKELLFNEQDNDEHMGYLADVTKPIIFSMARLDTVKNITGLTEWFGKNKRLRSLVNLVVVAGFFDPSKSKDREEMEEIKKMHELIEKYKLKGQMRWIAAQNDRTRNGELYRCISDTKGAFVQPALYEAFGLTVIEAMNCGLPTFATNQGGPAEIIVDGVSGFHIDPVNGDESSNKIADFFTKCKVDGEYWDRVSQAGLQRIYECYTWKMYANKALNMGSMYGFWRQLNKETKQAKQRYIDILYNLQFKNLAKTIEIPDFVTPKLQEPVKTEPTKPLQEARPREPVQKLVPEETRLPKLELTKLGQPNLMSNARKPLIVLVSVLIVAYASKNLYRRYFK
ATGGCGGAACGTGTACTCACTCGTGTTCACAGTCTTCGTGAGCGTCTCGATTCAACTCTCGCAACTCATCGTAATGAAATCCTCTTGTTTCTTTCAAGGATTGAAAGCCATGGAAAAGGAATATTGAAGCCTCATCAAGTTATGACTGAATTTGAAGCTATCTGCAAAGAAGATCAGAGCAAACTCTCTGATGGTGCTTTTTATGAAGTTCTTAAATGCACACAGGAAGCAATAGTGCAACCTCCATGGGTTGCACTCGCGATCCGTCTTCGACCCGGTGTTTGGGAATATGTTAGAGTCAATGTTAATGTTTTGGTGGTTGAAGAATTAAGTGTTCCTGAATATCTTCACTTCAAAGAAGAATTGGTTAATGGAACATCGAATGGCAACTTCGTGTTGGAACTGGATTTTGAACCTTTTACCGCATCGTTTCCTCGACCAACTTTAACCAAGTCTATTGGTAATGGTGTTGAGTTTCTAAACAGACATTTATCTGCTAAAATGTTTCATGATAAGGATAGCATGCACCCTCTTCTTGATTTCCTACGGACTCACCACTATAAGGGAAAGACAATGATGTTGAATGATAGAATCCAAAACCTCAATGCTCTACAATCGGTGTTGCGAAAGGCGTCAGAGTACTTATCAACACTCGACGCAGCAACACCGTACTCTGAGTTTGAACATAAGTTTCAAGAAATCGGGTTGGAGAGAGGTTGGGGTGATAAAGCGGAGGTCGTAATGGAGATGATCCACATGCTTCTAGACCTTCTAGAAGCACCCGACGCATGCACACTCGAGAAGTTTCTCGGAAGAATCCCAATGGTTTTCAATGTTGTCATTCTTTCGCCTCACGGCTACTTCGCCCAAGAAAATGTGTTGGGATATCCCGACACTGGCGGTCAGGTTGTTTACATCTTGGATCAAGTTCCCGCTCTGGAACGCGAGATGCTCAAAAGGATTAAGGAGCAAGGACTCGATATCATTCCTCGTATATTGATTGTTACGAGGCTTCTTCCCGACGCGGTTGGGACCACATGCGGGCAACGTTTAGAGAAAGTGTTTGGAGCCGAACACTCGCATATTCTTCGGGTCCCGTTTAGAACCGAAAAGGGTATTCTTCGTAAATGGATCTCTCGTTTTGAGGTGTGGCCTTACATCGAGACTTTCACCGAGGATGTTGCTAAAGAAGTTACAGCAGAGTTGCAAGCAAAACCAGATTTGATCATTGGAAACTATAGTGAAGGAAATTTGGTTGCATCTTTGCTAGCTCACAAGTTGGGTGTCACTCAGTGTACCATTGCTCATGCTTTGGAGAAAACTAAATACCCGGATTCTGATATCTACTGGAAGAACTTTGAGGAGAAATATCATTTCTCTTCGCAGTTTACCGCTGATCTTATCGCTATGAACCATACCGACTTCATCATCACCAGTACTTTCCAAGAAATTGCTGGAAGTAAGGACACGGTTGGACAGTACGAGAGTCATACCGCGTTCACAATGCCGGGATTGTATCGGGTGGTTCACGGGATCGATGTTTTTGACCCCAAATTCAATATTGTTTCACCCGGGGCCGATATGGGAATTTACTACTCGTATACCGAGAAAGAAAAGAGGCTCACTGCGCTTCACCCTGAAATCGATGAACTTCTCTTTAGTTCCGTCGAAAACGAAGAACACTTATGTGTGTTGAAGGATAAGAGTAAACCAATCTTGTTCACAATGGCGCGATTGGATAATGTGAAGAATTTAACCGGACTGGTTGAATGGTACGCTAAAAACGACCGCCTTCGTGAGCTCGTGAACCTCGTGGTCGTCGGTGGTGACCGAAGGAAAGAGTCGAAAGATCTTGAAGAACAAGCTCAGATGCAGAAGATGCATGAACTTATCGAAACCTACAAACTCAACGGTCAGTTCAGGTGGATATCCTCACAAATGAACCGCGTGAGGAACGGTGAGTTGTATCGCGTTATTGCTGACACACGAGGTGCGTTTATCCAGCCTGCGTTTTACGAGGCGTTTGGGTTGACGGTTGTGGAGGCCATGACTTGTGGCCTGCCGACATTCGCGACACTTCATGGTGGGCCCGCTGAGATTATTGTTCACGGGAAATCCGGGTTCCATATTGACCCGTATCACGGTGACCAGGTCACCGAGTTGCTGGTCAATTTCTTTGAGAAAACTAAACAAGACCCGGGTCATTGGGAGGCCATTTCCAAGGGTGGTCTGCAACGTATTCAGGAGAAATACACGTGGCAGATTTATTCAGATAGGTTGTTGACGCTTGCCGGAGTTTATGGATTCTGGAAGCATGTGTCGAAGCTTGACAGGCTCGAGATCCGTCGTTATCTTGAAATGTTTTACGCGCTCAAGTATCGCAAACTGGCTGAATCTGTTCCATTGGCTGTTGATGAGTGA
ATGGCGACAAGTAAGTTGAGCAGAACGCATAGTATGCGTGAGCGTGTTGAAGAAACTCTTTCCGCTCATCGCAACGAAATCGTTTCTCTTCTTTCTAGGTATGTGGCTCAGGGGAAGGCGATATTGCAGCCGCATCAGATACTCCATGAACTTGAGAATATCATCGGTGATGTTACTTCGCGCCAAAAGCTTACAGATGGTCCGTTTGGAGATGCGTTGAAGACAGCACAGGAATGTATAGTTCTACCTCCATTTGTAGCTTTAGCAGTTCGTCCAAGACCTGGTGTTTGGGAATACGTGCGCGTGGATGCATATCAACTAAGTGTGGAACAACTAACTGTTTCAGAGTATCTTACCTTCAAAGAAGAACTTGTTGGAGAGTCTAATAGTTCTTTAATGCTCGAGTTGGATTTTGAGCCATTTAATGCTTCGTTTCCTAGACCAACCCGTTCTTCATCCATTGGCAATGGAGTTCAGTTCCTGAATCGCCACCTGTCGTCAAGCATGTTTCGCAGCAAAGATTGTTTAGAACCGCTTCTGGATTTCCTACGCACACACAGACATAATGGACATGTAATGATGTTAAATGACCGCATAACAAGCATGACTAGACTTCAATCTTCTTTGGTCAAAGCAGAGGAATATCTTTCTAAACTACCATCTGATACAGACTACTCTGAGTTTCAATATGAATTGCAAGGAATGGGTTTTGAAAGAGGATGGGGAAACAATGCTGAAAGAATCATTGAGATGATGCATCTTCTCTCAGACATTCTACAAGCTCCAGATCCTTCCATTTTGGAATCTTTTCTTGCTAGAATACCTATGGTGTTTAATGTTGTTATATTATCAATACATGGCTACTTTGGGCAAGCAAATGTTTTGGGTTTGCCAGATACTGGTGGCCAGATTGTATATATATTGGATCAAGTCCGTGCATTGGAAAATGAGATGCTTCTTAAATTAAAGCACCAAGGACTGGATATCAAACCTAGGATTCTGATTGTGACTCGGTTAATACCTGATGCAAAAGGTACTTCATGTAACCAACGACTGGAAAGAGTCAGTGGAACTGAACACACACATATACTTCGTGTTCCTTTTAGAACCGAGAAAGGAATTCTTCGTAAATGGATCTCAAGGTTTGATGTATGGCCTTTTTTGGAGAAATTTACACAGGATGCAGCAAGTGAAATTTCTGCTGAGTTGCATGGTACTCCAGATCTTATAATTGGAAATTATAGTGATGGCAATCTTGTTGCCTCTTTATTATCTTACAAAATGGGAGTAACCCAGTGTAACATTGCTCATGCTTTAGAGAAAACAAAGTATCCAGATTCTGATTTATATTGGAAGAAATTTGATGAGAAATATCACTTTTCTTGTCAATTTACTGCTGATCTTTTAGCCATGAACAATGCAGATTTTATCATCACCAGCACATACCAAGAAATCGCGGGAACGAAAAATACTGTCGGACAATACGAGAGTCATTCGTCTTTCACTCTCCCGGGGCTCTACAGGGTTGTTCATGGTATTGACGTTTTTGACCCTAAGTTCAACATTGTGTCTCCAGGGGCAGATATGTCTATATACTTCTCATACACCGAGAAGGAAAAAAGACTTACATCTCTTCATACTACAATTGAGAAGTTATTGTTTGACCCTACACAAACTGAAGATTACATTGGAAATCTGAGTGATAAATCAAAACCGATAATTTTTTCAATGGCAAGACTTGATCATGTGAAGAACATTACGGGTCTGGTTGAGTGGTACGCTAAGAATGAGAAGCTTAGAGGACTAGCAAACCTTGTTGTGGTTGCTGGTTATAATAATGTGAAGAGGTCTAGTGACAGAGAAGAAATTGCAGAAATTGAAAAAATGCATCAACTTATTAAGAAATACAAATTAGATGGTCAGATGAGATGGATTTCAGCACAAACAAACCGCGCACAAAATGGTGAACTTTATCGCTATATTGCTGATGGAAGGGGAATCTTTGTACAGCCCGCTATTTATGAAGCTTTTGGGCTGACAGTGGTGGAGGCCATGACTTGTGGGCTTCCAACATTTGCAACTTGCCATGGTGGGCCAGGAGAGATAATTGAAAATGGTGTTTCGGGCTTCCATATCGACCCGTATCATCCGGATACTGCATCAGCCACAATGGCTGATTTTTTTCAGAAATGCAAGGAGGACCCGAGTTATTGGTTCAAGATATCTGAAGCAGGGCTTAAAAGAATATATGAAAGGTACACATGGAAAATTTACTCTGAACGGTTGATGACATTAGCTGGAGTTTATAGCTTCTGGAAGTATGTCTCGAAACTTGAGAGACGTGAAACAAGACGATATCTTGAGATGTTTTATATTCTTAAGTTCCGTGATCTGGTAAAATCTGTTCCAGTGGCTACTGATGATGAGGCTTAG
ATGGCGACACCTAAGCTTACGCGAACACCAAGCATGCGAGAGCGTCTTGAAGAAACTTTATCAGCTCATCGCAACGATATCGTCTCTCTTCTTTCCAGGTATGTAGATCAAGGTAAGGCCATATTGCAGCCCCACCACCTACTTGACGAAATCGATAACTTCATCGGAGATCAAAATTGCCGCCAAAAGCTTGCTGATAGTCTATTCGGTGAAATCCTCAAGTCCGCACAGGAAGGTATAATTCTTCCTCCATATGTAACGCTTGCTGTTCGTCCAAGACCTGGTGTTTGGGACTTTTTGCGTGTGAATGTCGATGAATTGAGTGTCGAGCAACTTACTGTTTCTGAGTATTTAAGCTTCAAGGAGGAGCTTGTAGATGGCCAGAGTAGGAACCCGTTTGTGTTGGAACTGGATCTGGAACCGTTTAATGCAACATTTCCCCGGATGTCACGATCTTCATCCATCGGCAATGGAGTTCAGTTTCTCAACCGTCATCTCTCGTCAATTATGTTTCGCAACAAAGATTGTATGGATCCGTTTCTTGATTTCCTTCGTGCTCATAAACATAAAGGATACGCGATGATGTTGAATGATCGGATACAAACAATGTCTAGACTTGAATCTTCTTTAGCAAAAGCGGAGGATCATCTCTCTAAACTACCACCCGAAACACCGTACTCCGAATTCGAATACGTATTGCAAGGAATGGGGTTTGAAAGAGGTTGGGGGGATAATTGTGAAAGAGTTCTTGGTATGATGCATCTTCTTTCTGACATTCTTCAAGCTCCAGATCCTTCGATTCTTGAAAAGTTTCTTGGAAAGATGCCGATGATCTTCAATGTTGTTGTGTTATCGATTCATGGTTACTTTGGTCAGGCTAATGTTTTGGGTTTGCCGGATACCGGTGGTCAGGTTGTATATATATTGGATCAAGTACGTTCTTTGGAGAATGAAATGTTACTTAAATTAAGGCATCAAGGACTTGATATCAAACCCAAGATTCTAATTGTAACTCGATTGATACCAAATGCCAAAGGTACTTCATGCAACCAACGATTGGAGAAAGTAAGTGGAACCGAATACACGTATATATTACGTGTCCCTTTTAGGACAGAGAAAGGGATTCTTGGTAAATGGTTATCAAGGTTTGATATATGGCCTTATTTGGAGGCGTTTACAACGGATGCAGCAAGTGAAATTGCTGCTGAGTTACACGGTGTTCCGGATCTTTTAATAGGAAACTACAGTGATGGGAATCTCGTTGCCTCCTTGCTATCTAACAAATTGGGCGTAACCCAGTGCAACATTGCACACGCGTTAGAGAAAACAAAGTATCCAGATTCCGACTTATATTGGAAGAAATTTGAGGACAAATATCACTTTTCATGTCAATTTACCGCCGACCTTCTAGCAATGAACAATGCAGATTTTATCATCACTAGCACATACCAAGAGATTGCAGGAACGAAAAACACCGTTGGACAATACGAGAATCATTCATCGTTCACTCTTCCGGGTCTATACAGGGTTGTTCACGGTATCGATGTCTTTGACCCGAAGTTCAACATCGTGTCACCAGGGGCAGATATGGCAATTTACTTCTCATATGCCGATAAAGAGAGACGACTTACATCTCTACATCCCACAATTGAGAAGCTATTGTTCGACACTGAGCAGAACGATGTACACATTGGAAATATAAATGACCCGTCTAAACCCATGATTTTCACAATGGCGAGGCTTGATCATGTGAAGAATATAACTGGATTCGTCGAGTGTTATGCTAAAAATAATAAGTTGAGGGAACACGCAAATCTTGTGGTTATTGCTGGTTATAATGACGCGAAGAAATCAAGTGATCGAGAAGAAATTGCGGAAATTGAAAAGATGCATAATCTTATCAAGCAATACAAACTTGATGGTCAGATGAGATGGATATCAGCCCAAACAAACCGGGCCCGAAATGGGGAATTTTATCGGTATATCGCTGATGGTAGGGGCGTTTTCGTCCAGCCCGCTTTCTATGAAGCATTTGGGCTTACGGTTGTGGAGGCGATGACATGTGGGCTCCCAACATTTGCCACGTGTCATGGTGGGCCTGCTGAGATCATTGAGGATGGTGTGTCGGGGTTCCATATTGATCCATATCATCCTGATAAGATGTCGACTACGTTAGCTGATTTTTTTCAAAAGTGCAAAGAGGAACCTAGTTACTGGGGTAAAATATCCGATGGCGGGCTGAAAAGAATAAGTGAAAGGTACACATGGAAGATATATTCGGAACGGTTGATGACGTTGGCGGGCGTATATAGCTTTTGGAAATATGTGTCAAAACTCGAGAGGCGTGAAACCCGTCGATACCTTGAGATGTTCTACATTTTAAAGTTTCGTCAACTGGTGAAGTCGGTTCCGCTAGCTGTTGATGAGGAGCCGTAA
ATGGCATCTGCTTCAAGTTCTATCATGAAACGGTCTGAATCAATAGTTGACACCATGCCAGAAGCCTTAAAGCAGAGCCGCTATCATATGAAAAAATGTTTTCTAAAATATGTAGAAAAAGGAATTCGCATGATGAAAAGACATCATTTGATACAAGAAATGGAGACCGCAATTGAAGACAAGGATGAAAAGGCTCAGCTTCTAGATGGCTTACTTGGCTACATCTTGTGCACAACTCAGGAAGCAGCCGTTGTTCCTCCTTGTGTTGCATTTGCTATAAGACCGAATCCTGGATTCTGGGAGTTTGTTAAAGTCAACTCTAATGATCTATCGGTTGATGGGATAACTGCCACAGATTACTTGAAGTTCAAGGAAATGATCGTAGATGAGACATGGGCTAAAGATGAAAATGCATTGGAGATTGACTTTGGATCGATGGACTTTAACCTACCAAACATGAGTTTATCTTGTTCGATTGGAAATGGTGTTAACTTCACATCAAAATTCATTACTTGTAAACTTTACGCACAATCTAGTTGCCAACAACTGCTTGTTGATTACTTGCTCTCATTGAATCATCAAGGAGAAAATCTTATGATCAATGATGCATTAAACTCAGTCTCAAAACTTCGAGCGGCTTTAATTGTAGCTCATGCGTCGCTATCTTCGTTGCCCAACGATACTCCATATCAAAGCTTCGAGCTTAGATTCAAAGAATGGGGATTTGAGAAGGGATGGGGAGATAACGCGGAACGCGCGAGGGAAACAATTCGGTTTCTTTTGGAGGTTCTTCAAGCACCCGATCCGATAAACCTCGAGGCTTTATTCAGCAGGATTCCAAACATATTCAACGTTGTTTTATTCTCGATTCATGGGTATTTTGGTCAATCCAATGTTCTTGGATTGCCCGATACTGGTGGCCAAGTGGTTTATGTTTTGGATCAAGTGGTAGCTATGGAAGAAGAACTACTCATGAGGATCAAACAACAAGGACTCAACTTCAAGCCTCAAATTCTTGTGGTGACCCGACTTCTTCCTGATGCTAAAGGGACCAAGTGTAATCAGGTGTTGGAACCAGTTCTGAACACGAAACATTCGCATATTCTTAGGGTTCCATTCAGGACTGATAAAGGTGTTCTTCGTAAATGGGTATCTCGATTTGATATCTATCCATATCTCGAAAACTTCACTCAGGATGCAAGTGCGAAAATCATTGAAATGATGGAAGGGAAACCGGATCTTATCATCGGAAACTATACCGATGGAAACCTTGTTGCATCACTCATGGCTAACAAACTCGGAACGACATTGGGAACAATTGCACATGCTTTGGAGAAAACCAAATACGAAGATTCAGACATGAATTGGAAGCAATTCGACCCAAAATATCACTTCTCCTGCCAATTTACAGCCGATATGATTGCAATGAACTCAGCTGATTTCATCATCACAAGTACTTTCCAAGAAATCGCTGGAAGTAAAGATAGACCCGGACAATATGAAAGCCATGAAGCATTTACACTTCCAGGATTATACAGAGTTGTTTCAGGCATCAACGTGTTCGATCCCAAATTCAATATCGCGTCTCCAGGAGCCGATCAAACCGTTTATTTCCCGTACACCGAAACAAAGAAACGATTCACTGCATTTCAACCCGCCATAGAGGAATTACTCTTCAGTAAAGTTGAAAACGAAGAACACATTGGATACTTAGAAGACAAAACCAAACCGATCATATTCTCAATGGCGCGTCTCGACACAGTTAAGAACATAACAGGACTAACCGAATGGTTTGGAGAGAACAAACGGCTCCGAAGCTTGGTTAATCTTGTAATCGTGGCGGGTTTCTTTGACCCGTCAAAGTCAAAAGACAGAGAAGAAATGGCGGAAATAAAGAAAATGCATTTATTGATTGAAAAATATCAGCTTAAAGGTCAAATAAGATGGATTGCTGCACAAACTGATAAGAACCGAAACAGTGAGCTTTACCGGTTTATTGCTGACTCAAAAGGCGCGTTTGTGCAGCCCGCTTTGTATGAGGCGTTTGGGCTCACGGTTATTGAGGCGATGAACTGTGGTTTACCGACTTTTGCAACTAATCAAGGTGGTCCAGCTGAGATTATCGTTGATGGTGTTTCTGGGTTCCAGATTGATCCTAATTTTGGTGATCAGTCTAGTAATAAGATTGCTGATTTCTTCCAGAAGTGTAAGGAAGATCCTGGTTATTGGAATAATATTTCAGAAGGCGGTTTGAAGCGTATATACGAATGTTATACTTGGAAGATTTATGCGAATAAAGTGTTGAATATGGGGAACATATACTCGTTTTGGAAGCGGTTAAACAAGGAACAAAAAGAAGCAAAACAAAGATACATTGAACTATTCTACAATCTACACTACAAGAACTTGGTTAGGACTGTACCAATTGCTAGTGATGAAGCTCAACCTGCACCAGTGTCAAGGGCAAAACTTGCAACACAACCCACAAGACGTACGCAATCCAGGTTGCAAAGGCTGTTTGGAGCTTAA
ATGGCAGCTTCTTCAAGTCCCATTATGAAACGGTCTGAGTCAGTACTCGACACCATGCCAGAAGCTTTGAGGCAAAGTCGGTATCATATGAAAAAATGCTTTCTAAAATATGTAGGGAAAGGAAAGCGGATGGTGAAACTCCACCATTTGATGCAAGAAATGGAGACCGTCATTGAGGACAAGGACGAAAAGGCTCAGCTCTTGGAAGGCTTACTTGGTTACATCTTGTGCACCACTCAGGAAGCAGCAGTTGTTCCTCCTTATGTCGCCTTTGCAATAAGGCCAAACCCTGGATTTTGGGAGTTTGTTAAAGTCAACTCTAATGATCTCTCGGTTAAAGGGATCACTTCCACCGATTACTTGAAGTTCAAGGAAATGATCGTTGACGAAACATGGGCTAATGATGAAAATGCATTGGAGATCGACTTTGGAGCAATGGACTTTAACTTGCCAACAATGAGCTTATCTTCTTCAATTGGAAATGGAGTTAACTTCACATCAAAGTTTATTATTTCTAAACTTTATGCTCATTCTGGCAGCCAATTACAATCTCTAGTTGATTACTTACTTTCATTAAATCATCAAGGAGAAAAACTTATGATAAATGACAAACTAAACACAGTTTCAAAACTTCAAGCCGCTCTAATAGTAGCTCATTCTTTCCTTTCTTCATTGCCCAACGACACACCGTATCAAAGCTTTGAACTTAGATTTAAAGAGTGGGGTTTTGAAAAAGGATGGGGAGATTATGCAGAAAGGGTGCAAGAAACAATTCGGTTTTTGTTGGAGGTTCTTCAAGCACCCGACCCCGTAAACCTAGAGGCCTTTTTTAGCAGGGTTCCAAACATATTCAATATTGTTTTATTCTCGATTCATGGGTATTTTGGTCAATCCAATGTTCTTGGCTTGCCCGATACCGGAGGTCAGGTAGTTTATGTTTTGGATCAAGTTGTGGCAATGGAAGAAGAATTGCTACTTAGGATTAAGCAACAAGGACTCAGCTTCAAGCCTCATATTCTTGTGGTGACTCGACTTCTTCCCGATGCCAAAGGGACCGAGTGTAGCCAAGTTTTGGAACCAGTTCTCAACACGAAACACTCACACATTCTTAGAGTCCCATTTAGGACAGAAAAAGGTGTTCTTCGTAAATGGGTGTCTCGATTTGATATCTATCCATACCTCGAAAAGTTTACTCAGGATGCAAGTGCAAAAATAACTGAAATGATGGAAGGAAAACCTGATCTTATCATTGGAAACTACACTGACGGAAACTTGGTTGCATCTCTCATGGCTAACAAACTCGGAAGCACATTGGGAACGATTGCACACGCGTTAGAGAAGACTAAATACGAAGATTCAGACATGAAATGGAAACATTTGGACACAAAATATCACTTTTCTTGTCAATTTACAGCTGATATGATAGCAATGAATTCAGCAGATTTCATCATCACTAGTACTTTCCAAGAAATTGCTGGAAGTAAAGATAGACCCGGTCAGTATGAAAGCCATGAAGCATTTACACTCCCGGGTTTATATAGAGTTGTTTCGGGCATCAACGTGTTTGATCCCAAATTCAACATTGCATCTCCGGGAGCTGATCAAACCGTTTATTTCCCTTACACGGAAACACCAAAACGATTCACTACTTTTCAACCCGCTATACAAGAATTACTCTTTAGTAAAGTTGAAAACGACGAACACATTGGATATTTAGAAGATAAGAATAAACCAATCATCTTCTCAATGGCAAGACTCGACATGGTTAAGAACATAACGGGGCTAACCGAATGGTTTGGGGAAAACAAGCGGTTAAGAAGTTTGGTTAATCTTGTAATTGTGGCGGGGTTTTTTGATCCGTCAAAATCAAAAGATAGAGAAGAAATGGAAGAAATAAAGAAAATGCATTTGTTGATTGAGAAATATGAACTTAAAGGTCAAATAAGATGGATAGTAGCACAAACTGATAAAAACAGAAATAGTGAACTTTATCGTTGTATCGCTGACTCAAAGGGGGCGTTTGTGCAACCGGCTTTATATGAAGCGTTTGGGTTAACCGTTATTGAGGCTATGAATTGTGGGTTACCAACTTTTGCAACTAACCAAGGTGGTCCGGCTGAGATTATTGTTGATGGTGTTTCTGGGTTCCAAATCGATCCTAATTATGGCGACGAGTCTAGCAACAAGATCGCTGATTTTTTTCAAAAATGCAAACAGGATCCAGGATACTGGAATAGGATTTCAGACGGTGGTTTGATGCGTATATACGAATGCTACACATGGAAGATTTATGCAAATAAAGTGTTGAATATGGGGAACATTTACACATTTTGGAAGCAGTTAAACAAGGAACAGAAAGATGCGAAACAAAGATACATTGAGCTATTCTACAATCAACATTACAAGAATTTGGTTAGGACTGTGCCGATTGTAAGTGATGAAGATGACCAAGTTACAAGGGCAAAACCGGCAACACAACCTTCAACAAGGCGCACACAATCTGCCTTGCAAAGGCTGCTTGGAGCTTAA
ATGGATTTCGGTATAGCAGAGACTTTGGCCGAGGCATTGAAGCAAAACCGGTACCATGCAAGGAGATGCTTTGAGCGTTTTACATCACGTGGAAAAAGGATGGTGAAGCCTCAAGAGTTATTACACATGATTGAAAAAACCATTGACGACAAGCTTGAAAGAACGAAGGTCTTGGAGGGCTCAATGGGACAAATCTTGAGTTCCACACAGGAGGCAATCGTTATTCCACCATATGTTATTTTAGGATTGAGAGCGAATCCAGGACAATGGGCATACGTTAAGATCAATGCTGATGACGTCACTGTTGAGTCACTCACACCTTCACAATATCTAAAGTTCAAAGAATCCATCTACGATCAAGAATGGGCAAAGGACGAAAATGCCCTTGAACTAGATTTCGGAGCGTTCGACTTTGATACGCCTCGATTAATCCTCCCGTCATCTATCGGCAACGGACTCGGTTACATTTCAAAGTTCATGACTTCAAGAATTGGTGGTGATCTAGAAAACGCGAAGCCGTTGCTTGACCACTTGCTTGCTCTAAAATATCATGGAGAGAAGCTTATGATCAATGAGACAATAGATACAGTTTCAAAGCTCCAGAAAGCATTAATTGTTGCTGATGTCTACTTATCTGCACACCCGAAAGACGAACAATATCAAACCTTAGAGCCCAAGCTTAAAGAATGGGGATTTGAGAAAGGATGGGGAGATACTGCTGAAAGAGTTAGAGAGACAATGAAAATGCTTTCGGAGATTCTTCAAGCACCCGACCCGATTAACATGCAATCGTTCTTTAGCAGGCTTCCGGTGGTCTTCAATATTGTCATATTTTCTATTCATGGGTATTTTGGTCAATCAGATGTTCTTGGATTACCTGATACCGGAGGGCAGGTTGTTTACATTCTTGATCAAGTTAAAGCATTAGAGGAAGAGATATTGCTAAGAATAAAAATGCAAGGATTGAATGCAAAGCCTCGGATTCTTGTGGTGAGTCGACTCATTCCCGACGCACAAGGAACAAAGTGTAACGAGGAAATGGAACCGATCTTGAACACAATGCATTCACACATCCTTCGGGTTCCTTTCAGAACCTCAAAAGGCGTTGTTCCTCAATGGGTATCGCGGTTTGACATCTACCCGTATCTTGAAAGATTCTCACAGGACGCTGCCTCTAAAATACTTGAAGTAATGGAATGTAAACCAGATCTCATACTTGGAAACTACACAGATGGAAACATTGTTGCATCACTTATAGCCAAAAAGTTTGGAGTAACACAGGGGACGATTGCACACGCGTTAGAGAAGACAAAGTACGAAGATTCGGATGTTAACTGGAAAAACTTTGAAAAAAAGTATCATTTCTCATGTCAATTTACCGCGGATTTGATCTCAATGAACGCTGCAGATTTCATAATCACAAGCACTTATCAAGAAATTGTGGGAAGCAAACAAAGACCCGGACAGTATGAGACCCACGGGGCGTTTAGTATGCCCGGACTTTGTAGAGTCGTGTCGGGCATCAACGTGTTTGATCCTAAGTTCAACATTGCTTCACCCGGTGCGGAACAATCGGTTTATTTTCCGTACACCGAGAAGGAGAAACGGTTAACGGATTTTCATCCCGCAATTAAAGAACTACTTTTCAACGAACAAGACAATGACGAGCATATGGGATACCTCGCGGATGTAACCAAACCGATAATATTCTCAATGGCGAGGCTCGATACGGTGAAGAACATAACAGGGTTAACCGAGTGGTTCGGTAAGAACAAACGACTTAGAAGTCTTGTAAACTTGGTTGTTGTCGCGGGGTTCTTCGATCCATCAAAATCTAAAGACCGTGAAGAGATGGAGGAAATCAAGAAAATGCATGAACTAATAGAGAAATACAAACTCAAGGGTCAGATGAGATGGATCGCGGCTCAAAACGATAGGACCCGCAATGGTGAATTGTATCGGTGTATTTCCGATACGAAGGGAGCGTTTGTGCAGCCCGCGTTGTATGAGGCTTTTGGGCTCACGGTTATCGAGGCAATGAACTGCGGTCTCCCGACTTTTGCAACCAATCAAGGCGGGCCCGCGGAGATCATAGTTGACGGAGTTTCGGGATTTCATATTGATCCCGTTAACGGAGATGAATCAAGCAACAAGATTGCTGATTTCTTCACGAAATGCAAAGTCGATGGCGAGTATTGGGACCGCGTGTCGCAAGCGGGACTTCAACGTATTTACGAGTGCTACACATGGAAGATGTATGCTAACAAAGCATTGAACATGGGTTCGATGTATGGTTTTTGGAGGCAATTAAACAAAGAAACTAAGCAAGCGAAGCAACGATACATCGATATCTTGTATAACTTACAATTCAAGAATTTGGCAAAAACCATTGAAATCCCTGATTTTGTGACTCCTAAACTTCAAGAACCGGTCAAAACCGAACCAACAAAACCATTACAAGAAGCAAGACCTCGAGAACCGGTGCAAAAACTGGTACCGGAAGAAACCCGACTGCCAAAACTAGAGTTGACCAAGCTTGGTCAACCGAATTTGATGAGCAATGCAAGAAAACCATTGATTGTTCTTGTTTCTGTGTTGATAGTTGCATATGCATCCAAGAACTTGTATAGGAGGTATTTCAAATAG
本発明は、グリコシルトランスフェラーゼを提供する。本発明のグリコシルトランスフェラーゼは、1次、2次、および/または3次グリコシル化をすることができる。ある実施形態においては、グリコシルトランスフェラーゼは、1次、2次、および3次グリコシル化をすることができる。他の実施形態において、グリコシルトランスフェラーゼは、2次、および/または3次グリコシル化をすることができる。ある実施形態においては、グリコシルトランスフェラーゼは、UDP‐グリコシルトランスフェラーゼを含むが、これに限定されないグルコシルトランスフェラーゼである。グルコシルトランスフェラーゼは、UGT76G1もしくはUGT74G1などのステビア レバウディアナのUDP‐グルコシルトランスフェラーゼ、またはOs03g0702000などのイネのグルコシルトランスフェラーゼを含むが、これらに限定されない。他の実施形態において、本発明は、シクロデキストリングルカノトランスフェラーゼを提供する。スクロースシンターゼもまた提供する。
本発明は、カンナビノイドグリコシドプロドラッグの生成方法、および本方法によって生成されたカンナビノイドグリコシドプロドラッグをさらに提供する。本方法は、in vitroまたはin vivoにおいて(細胞系において、または植物内において)実行され得る。ある実施形態においては、カンナビノイドグリコシドプロドラッグの生成方法であって、該方法は、1または2以上のグリコシルトランスフェラーゼの存在下で、1または2以上の糖供与体とともに、カンナビノイドアグリコンをインキュベートする工程を含む、カンナビノイドグリコシドプロドラッグの生成方法を提供する。
グリコシル化反応は、50mMのKPO4、pH7.2、3mMのMgCl2、0.005%のCBD、2.5%のUGT76G1精製酵素調製物、および2.5mMのUDP‐グルコースからなる。バッファーを脱気し、チューブを窒素によってパージし、反応を光から保護して、28℃で、180rpmのアジテーションをしながら、18時間インキュベートした。それから反応を、等量のエチルアセテートによって3回抽出し、蒸発させて乾燥させ、半分の容量のHPLCグレードのメタノールに溶解した。50マイクロリットルを、逆相C18カラムに注入し、10%からはじまり、99%まで増加するアセトニトリルの勾配によって、溶出させた。ピキア パストリスにおける発現によって、UGT76G1を生成し、標準的な分子生物学的技術によって精製した。UGT76G1酵素は、UDP‐グルコース依存的に、CBDをグリコシル化することがわかった。この活性は、存在するUDP‐グルコースの量に比例した。インキュベーション温度は、28℃であり、高い温度は、CBDの有意な分解を引き起こし得ることから、許容可能な範囲は、20℃から30℃であろう。基質の光分解を防ぐために、反応は、暗闇において実施された。120から200rpmの穏やかなアジテーションを、不活性雰囲気下で、反応液を混合するために用いた。
組換えOs03g0702000酵素を、UGT76G1に対して相対的に1:2の比率で含むこと以外は、実施例1に記載した通りに酵素反応を実施した。サンプルを、実施例1と同様に抽出および分析した。組換えOs03g0702000酵素を、コドン最適化し、大腸菌BL21‐DE3細胞において発現し、固定化金属イオンクロマトグラフィーによって精製した。
組換えシクロデキストリングルカノトランスフェラーゼ(CGTアーゼ、Toruzyme 3.0L、商標名、ノボザイム株式会社)を、UDPGまたはUGT76G1を用いなかったこと以外は、実施例1において示されるように、反応に加えた。マルトデキストリンは、最終濃度0.05%で用い、Toruzyme 3.0Lは、0.1%で用いた。実施例1と同様に、サンプルを抽出および分析した。さらに、カンナビノイドをカンナビノイド‐グリコシドへと変換するために、実施例1からの反応を実行し、それからCGTアーゼおよびマルトデキストリンを追加し、十分な時間を与えて、カンナビノイド‐グリコシドとともにインキュベートした。結果的に得られた生成物は、カンナビノイド骨格上でのβ‐グリコシル化、および1次糖から発するα‐グリコシル化を含む。この追加の処理は、β‐プライムド,α‐グリコシル化カンナビノイド(β‐primed,α‐glycosylated cannabinoid)と称される、新しいカテゴリーの化合物を生成した。
上述した生体触媒反応によってグリコシド生成物を生成し、C18固相精製によって、均質に精製した。100mg Hypersep C18カラム(Thermo)をメタノールによって水和し、50%のメタノール水溶液でリンスし、水でリンスし、グリコシル化反応をカラムに通過させ、水で洗浄し、10%、20%、および30%のメタノールで洗浄し、グリコシド生成物を、45および60%のメタノール水溶液によって溶出させた。溶出液を乾燥し、エチルアセテートによって抽出し、乾燥させて完成させ、さらなる分析および試験のための、95%より純粋なカンナビノイド‐グリコシドを生成した。
カンナビノイドアグリコンCBD、CBDV、Δ9‐THC、CBN、1‐AGおよび2‐AG、DHEA、AEA、カプサイシン、ならびにバニリンのグリコシル化反応の反応生成物のHPLCライントレースを、図16から24に、それぞれ示した。酵素反応は、実施例1に記載された通りに実施した。実線は、開始アグリコンの溶出プロファイルを示し、点線は、グリコシル化反応生成物混合液の溶出プロファイルを示す。
図16のHPLCライントレースに示したように、投入したCBDアグリコン(VB101、13.65’)は、+65時間のインキュベーション時間の後に、元の量の5%が枯渇した。CBD‐グリコシドは、HPLCカラムから、8.87、9.02、9.97、10.33、および10.37分において、溶出された。グリコシル化生成物を、LCMS分析によって同定した。グリコシル化生成物「g1」はモノグリコシドであり、「g2」はジグリコシドであり、「g3」はトリグリコシドであり、および「g4」はテトラグリコシドである。LC−LRMSは、島津製作所製のLC−MS 2010 EV装置で実施した。用いたLCカラムは、Silia Chrom XDB C18 5um、150A、4.6×50mmであった。メソッドは、12分間、5から95のH2O:ACN勾配であった。LRMSのために、エレクトロスプレーイオン化(ESI)を、ポジティブモードで実施した。
実施例6Aを実施したのと同様の方法によって、Δ9‐THCのグリコシル化反応の生成物(図18のHPLCライントレースに示した)を、LCMS分析によって同定した。
図27は、単離されたVB104の1NMRスペクトルを示し、図28は、単離されたVB110の1H MRスペクトルを示す。これらそれぞれの生成物は、CBDのグリコシル化反応によって生成された反応混合液から単離された。CD3OD中で調製されたそれぞれの化合物の10 mg/ml溶液の1H NMRスペクトルを、TopSpin acquisition and processingソフトウェアを用いて、Bruker Avance II 400 MHz装置で得た。
C18保持時間は、ダイオードアレイ検出器(Diode Array Detector)を備え付けたDionex HPLC上のPhenomenex Kinetex 2.6u 100A C18カラム上でのアセトニトリルの増加の直線傾斜によって、経験的に決定された。表AのCLogP値は、ChemDraw(CambridgeSoft)によって予測した。参照カンナビノイドを、HPLCによって分析し、logP値(http://pubchem.ncbi.nlm.nih.gov/)を確立し、図29に示すように、キャリブレーションラインを作成するために用いた。予測されたcLogP値は、参照キャリブレーションラインと相関関係があった。図29に示すように、C18逆相HPLC保持時間を、表Aに示すcLogP値に対してプロットした。データポイントの番号は、表の番号と関連している。白地のダイヤモンドは、新規のカンナビノイドグリコシドを示し、黒字のダイヤモンドは、参照カンナビノイドおよび誘導体を示す。ClogP値はChemDraw(CambridgeSoft)によって予測した。すべてのデータポイントについて、直線回帰を実施した(R2=0.9455)。
部位特異的な薬物送達に影響するグリコシル化の有効性を調査するために、経口的強制飼養によって、3匹のマウスにVB110を投与し、動物を、30、60、および90分の時点で殺した。8週齢のオスのスイスマウスを、12時間飢餓状態にし、その後、10%のエタノール米国薬局方(USP)、10%のプロピレングリコールUSP、0.05%のデオキシコール酸ナトリウムUSP、79.95%の生理食塩水 USP 中の120mg/kgのVB110を投与した。終了および組織摘出の後に、それから腸の内容物を抽出し、C18逆相HPLCによって分析した。図30Aに示すように、小腸の内容物は、完全なVB110を示したが、切断されたCBDを示さなかった。図30Bに示すように、大腸の内容物は、60および90分の時点において、VB110およびCBDの両方を含んでいた。このVB110の切断は、センノシドベータ‐グリコシドについてみられた大腸における切断と一貫しており、大腸の微生物叢から分泌されたベータ‐グリコシダーゼに起因する。
大腸におけるCBD‐グリコシドの代謝および切断を調査するために、CBD‐グリコシドの混合物の水性溶液を、経口的強制飼養によって、マウスに投与した。対照として、CBDのクレモフォール、エタノール、および生理食塩水溶液を、第2のマウスに投与した。マウスはそれぞれ、2時間目に殺した。終了および組織抽出の後に、それから腸の内容物を抽出し、C18逆相HPLCによって分析した。この実施例において用いられたマウスは、溶液の投与の前に12時間飢餓状態にした8週年のオスのスイスマウスである。
大腸におけるTHC‐グリコシドの代謝および分離を調査するために、経口的強制飼養によって、2匹のマウスにTHC‐グリコシドの混合物の水性溶液を投与した。第1の動物は、2時間目に殺し、第2の動物は、4時間目に殺した。終了および組織摘出の後、それから小腸の内容物を抽出し、C18逆相HPLCによって分析した。この実施例において用いられたマウスは、溶液の投与の前に12時間飢餓状態にした8週齢のオスのスイスマウスである。
多数の研究グループは、単純なUDPからUDPGへの再循環系を利用して、生成物の形成に必要なUDPGの量を減少させている(Hardin 2004,Bungarang 2013)。これらの研究は、葉組織で見つかった1次スクロースシンターゼのアイソフォームが、おそらくフルクトースをUDPGとともに反応させることによって、スクロースの合成を実行し、スクロースを生成して、UDPを消費することを特徴付けた。
SrSus4>SrSus1‐タグなし>SrSus6>SrSus2>SrSus1>6×His‐SrSus1>SrSus3
UGT酵素によるカンナビノイドグリコシドの形成は、ヌクレオチド糖供与体UDPGを、化学量論的な量、必要とすることから、グリコシル化反応の後、消費されたUDPを、再循環または再捕捉することには利点がある。ステビア レバウディアナに由来するSUS4アイソフォームを利用して、投入するヌクレオチドとしてUMPのみを使用して、カンナビノイドグリコシドを生成することに成功した。
Bartzokis G. (2004). Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiology of Aging. 25:5-18.
Bisogno T, et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology. 134, 845-852.
Chen Q, et al. (2009). Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J Drug Targeting. 17(4):318-328.
Conchie J., Findlay J., Levvy GA. (1958). Mammalian Glycosidases, Distribution in the body. Biochem J. 71(2):318-325.
De Petrocellis L, et al. (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology. 163, 1479-1494.
Dewitte G, et al. (2016) Screening of Recombinant Glycosyltransferases Reveals the Broad acceptor Specificity of Stevia UGT-76G1. Journal of Biotechnology. Accepted Manuscript, DOI: http://dx.doi.org/doi:10.1016/j.jbiotec.2016.06.034.
Friend DR., Chang GW. (1984). A Colon-Specific Drug-Delivery System Based on Drug Glycosides and the Glycosidases of the Colonic Bacteria. J Med Chem. 27:261-266.
Friend DR., Chang GW. (1985). Drug Glycosides: Potential Prodrugs for Colon-Specific Drug Delivery. J Med Chem. 28:51-57.
Gomez O., Arevalo-Martin A., Garcia-Ovejero D., Ortega-Gutierrez S., Cisneros JA., Almazan G, Sanchez-Rodriguez MA., Molina-Holgado F., Molina-Holgado E. (2010). The Constitutive Production of the Endocannabinoid 2-Arachidonoylglycerol Participates in Oligodendrocyte Differentiation. Glia. 58:1913-1927.
Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L. (2009). Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther. 15(1):65-75.
Jarh, P., Pate DW., Brenneisen R., Jarvinen T. (1998). Hydroxypropyl-beta-cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of delta9-tetrahydrocannabinol. Life Sci. 63(26):PL381-384.
Jiang R, et al. (2011) Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences. 89, 165-170.
Kren V (2008) Glycoside vs. Aglycon: The Role of Glycosidic Residue in Biologic Activity. Glycoscience. pp2589-2644.
Kren V, Rezanka T (2008) Sweet antibiotics - the role of glycosidic residues in antibiotic and antitumor activity and their randomization. FEMS Microbiol Rev. 32, 858-889.
Li S., Li W., Xiao Q., Xia Y. (2012). Transglycosylation of stevioside to improve the edulcorant quality by lower substitution using cornstarch hydrolyzate and CGTase. J Food Chem. 138(2013):2064-2069.
Mazur A., et al. (2009). Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids. Drug Metabolism and Disposition. 37(7):1496-1504.
Mecha M., Torrao AS., Mestre L., Carrillo-Salinas FJ., Mechoulam R., Guaza C. (2012). Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death and Disease. 3(e331).
Mechoulam R., Parker LA., Gallily R. (2002). Cannabidiol: An Overview of Some Pharmacological Aspects. 42(S1):11S-19S.
Mighdoll MI., Tao R., Kleinman JE., Hyde TM. (2015). Myelin, myelin-related disorders, and psychosis. Schizophr Res. 161(1):85-93.
Molina-Holgado E., Vela JM., Arevalo-Martin A., Almazan G., Molina-Holgado F., Borrell J., Guaza C. (2002). Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannavinoid Receptors and Phosphatidylinositol-3-Kinase/Akt Signaling. J. Neurosci. 22(22):9742-9753.
Noguchi A, et al. (2009). Identification of an inducible glucosyltransferase from Phytolacca americana L. cells that are capable of glucosylating capsiacin. Plant Biotechnology. 26, 285-292.
Pacher P, et al. (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacology Review. 58(3), 389-462.
Richman A., Swanso, A., Humphrey T., Chapman R., McGarvey B., Pocs R., Brandle J. (2005). Functional genomics uncovers three glucosyltransferases involved in the synthesis of the major sweet glucosides of Stevia rebaudiana. Plant J. 41(1):56-67.
Russo E., Guy, GW. (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses. 66(2):234-46.
Tanaka H., et al. (1993). Cannabis, 21.1Biotransformation of cannabinol to its glycosides by in vitro plant tissue. Journal of Natural Products. 56(12):2068-2072.
Tanaka H., et al. (1996). Cannabis 25, biotransformation of cannabidiol and cannabidiolic acid by Pinellia ternata tissue segments. Plant Cell Reports. 15:819-823.
Terao J., Murota K., Kawai Y. (2011). Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food Function. 2:11-17.
Thomas A., et al. (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2receptor agonists in vitro. British Journal of Pharmacology. 150, 613-623.
US Patent 8,410,064 B2. 2013. Classical cannabinoid metabolites and methods of use thereof.
US Patent 8,227,627 B2. 2012. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahyrocannabinol and methods of using the same.
Watanabe K, et al. (1998) Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. Life Sciences. 62(14), 1223-1229.
WO2009018389 A4. 2009. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same.
WO2012011112 A1. 2011. Non psychoactive cannabinoids and uses thereof.
WO 2014108899 A1. 2014. Fluorinated CBD compounds, compositions and uses thereof.
Yamaori S, et al. (2011) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sciences, 88, 730-736.
Zuardi AW, et al. (2012). A Critical Review of the Antipyschotic Effects of Cannabidiol: 30 Years of a Translational Investigation. Current Pharmaceutical Design, 18, 5131-5140.
Claims (79)
- 式(I)を有するカンナビノイドグリコシドプロドラッグ化合物、またはその薬学的に適合する塩:
(式中、Rは、H、β‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;
R’は、H、またはβ‐D‐グルコピラノシル、または3‐O‐β‐D‐グルコピラノシル‐β‐D‐グルコピラノシルであり;かつ
Aは、カンナビノイド化合物、エンドカンナビノイド化合物、またはバニロイド化合物の、ヒドロキシル基の反応を通して形成されたアグリコン部分構造である。)。 - 請求項1に記載の化合物であって、AはA’、A’’、またはA’’’であり、
A’は:
A’’’は:
- AはA’である、請求項2に記載の化合物。
- A’は:
であり;
Gは上述した通りである、請求項3に記載の化合物。 -
から選ばれる、請求項4に記載の化合物。 - A’は:
であり;
Gは上述した通りである、請求項3に記載の化合物。 -
- A’は:
である、請求項3に記載の化合物。 -
から選ばれる、請求項8に記載の化合物。 - A’は:
である、請求項3に記載の化合物。 -
- AはA’’である、請求項2に記載の化合物。
- A’’は:
-
- A’’は:
Gは上述した通りである、請求項12に記載の化合物。 -
- A’’は:
Gは上述した通りである、請求項12に記載の化合物。 -
から選ばれる、請求項17に記載の化合物。 - A’’は:
-
から選ばれる、請求項19に記載の化合物。 - AはA’’’である、請求項2に記載の化合物。
- A’’’は:
-
- A’’’は:
-
から選ばれる、請求項24に記載の化合物。 - A’’’は:
Gは上述した通りである、請求項21に記載の化合物。 -
- VB102、VB103、VB104、VB105、VB106、VB107、VB108、VB109、VB110、VB111、VB112、VB113、VB114、VB115、VB116、VB117、VB118、VB119、VB120、VB121、VB122、VB123、VB124、VB125、VB126、VB127、VB128、VB129、VB130、VB131、VB132、VB133、VB134、VB202、VB203、VB204、VB205、VB206、VB207、VB208、VB209、VB210、VB211、VB212、VB213、VB214、VB215、VB216、VB217、VB218、VB219、VB220、VB221、VB222、VB223、VB224、VB225、VB226、VB227、VB228、VB229、VB230、VB231、VB232、VB233、VB234、VB301、VB302、VB303、VB304、VB305、VB306、VB307、VB308、VB402、VB403、VB404、VB405、VB406、VB407、VB408、VB502、VB503、VB504、VB505、VB506、VB507、VB508、VB602、VB603、VB604、VB605、VB606、VB607、VB608、VB609、VB610、VB611、VB612、VB613、VB614、VB615、VB616、VB617、VB618、VB619、VB620、VB621、VB622、VB623、VB702、VB703、VB704、VB705、VB706、VB707、VB708、VB709、VB710、VB711、VB712、VB713、VB714、VB715、VB716、VB717、VB718、VB719、VB720、VB721、VB722、VB723、VB802、VB803、VB804、VB805、VB806、VB807、VB808、VB902、VB903、VB904、VB905、VB906、VB907、VB908、VB1002、VB1003、VB1004、VB1005、VB1006、VB1007、VB1008、VB1102、VB1103、VB1104、VB1105、VB1106、VB1107、VB1108、VB1109、VB1110、VB1111、VB1112、VB1113、VB1114、VB1115、VB1116、VB1117、VB1118、VB1119、VB1120、VB1121、VB1122、VB1123、VB1124、VB1125、VB1126、VB1127、VB1128、VB1129、VB1130、VB1131、VB1132、VB1133、VB1134、VB1135、およびVB1136から選ばれる、化合物。
- 請求項1から28のいずれか1項に記載の化合物、および薬学的に許容される担体、希釈剤、添加剤、またはアジュバントを含む、薬学的組成物。
- 被験者に対するカンナビノイド薬の部位特異的送達のための方法であって、請求項1から28のいずれか1項のカンナビノイドグリコシドプロドラッグを投与する工程を含む、方法。
- 前記カンナビノイドグリコシドプロドラッグは、経口投与のために調合されている、請求項30に記載の方法。
- 前記カンナビノイドグリコシドプロドラッグは、非経口投与のために調合されている、請求項30に記載の方法。
- 前記カンナビノイドグリコシドは、経皮投与のために調合されている、請求項30に記載の方法。
- 被験者に対するカンナビノイド薬の部位特異的送達のための方法であって、請求項29に記載の薬学的組成物を、それを必要とする被験者に対して投与する工程を含む、方法。
- 前記薬学的組成物は、経口投与のために調合されている、請求項34に記載の方法。
- 薬学的組成物は、非経口投与のために調合されている、請求項34に記載の方法。
- 前記薬学的組成物は、経皮投与のために調合されている、請求項34に記載の方法。
- カンナビノイド薬の被験者の血液脳関門を越える送達を容易にするための方法であって、請求項1から28のいずれか1項に記載のカンナビノイドグリコシドプロドラッグを、それを必要とする被験者に投与する工程を含む、方法。
- 有効量の請求項1から28のいずれか1項に定義されるカンナビノイドグリコシドプロドラッグを含む、抗微生物剤。
- 有効量の請求項1から28のいずれか1項に定義されるカンナビノイドグリコシドプロドラッグの、抗微生物剤としての使用。
- 有効量の請求項1から28のいずれか1項に定義されるカンナビノイドグリコシドプロドラッグを含む、洗浄剤。
- 有効量の請求項1から28のいずれか1項に定義されるカンナビノイドグリコシドプロドラッグの、洗浄剤としての使用。
- 1または2以上のグリコシルトランスフェラーゼの存在下で、1または2以上の糖供与体とともに、カンナビノイドアグリコンをインキュベートする工程を含む、カンナビノイドグリコシドの製造方法。
- 前記1または2以上のグリコシルトランスフェラーゼは、UGT76G1またはUGT76G1‐様グリコシルトランスフェラーゼである、請求項43に記載の方法。
- 前記1または2以上のグリコシルトランスフェラーゼは、Os03g0702000またはOs03g0702000‐様グリコシルトランスフェラーゼをさらに含む、請求項44に記載の方法。
- 前記1または2以上の糖供与体は、UDP‐グルコース、UDP‐グルクロン酸、UDP‐マンノース、UDP‐フルクトース、UDP‐キシロース、UDP‐ラムノース、UDP‐フルオロ‐デオキシグルコース、およびこれらの組み合わせからなる群から選ばれる、請求項43から45のいずれか1項の方法。
- 前記糖供与体は、UDP‐グルコースである、請求項46の方法。
- グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼの存在下で、UDP‐グルコースとともに、カンナビノイドアグリコンをインキュベートする工程を含む、カンナビノイドグリコシドの製造方法。
- グリコシル化が可能である条件下で、第1のグリコシルトランスフェラーゼおよび第2のグリコシルトランスフェラーゼの存在下で、1または2以上の糖供与体とともに、カンナビノイドアグリコンをインキュベートする工程を含む、カンナビノイドグリコシドの製造方法。
- 前記糖供与体はUDP‐グルコースであり、前記第1のグリコシルトランスフェラーゼはUGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼであり、および前記第2のグリコシルトランスフェラーゼはOs03g0702000またはOs03g0702000‐様グルコシルトランスフェラーゼである、請求項49に記載の方法。
- グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼ、およびOs03g0702000またはOs03g0702000‐様グルコシルトランスフェラーゼの存在下で、UDP‐グルコースとともに、カンナビノイドアグリコンをインキュベートする工程を含む、カンナビノイドグリコシドの製造方法。
- 前記カンナビノイドアグリコンは、カンナビノイド、エンドカンナビノイド、またはバニロイドである、請求項43から51のいずれか1項に記載の方法。
- 前記方法によって製造される前記カンナビノイドグリコシドは、請求項1から28のいずれか1項で定義される前記式(I)の化合物である、請求項43から51のいずれか1項に記載の方法。
- グリコシル化が可能である条件下で、シクロデキストリングルカノトランスフェラーゼの存在下で、マルトデキストリンとともに、カンナビノイドアグリコンをインキュベートする工程を含む、カンナビノイドグリコシドの製造方法。
- グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼおよびシクロデキストリングルカノトランスフェラーゼの存在下で、UDP‐グルコースおよびマルトデキストリンとともに、カンナビノイドアグリコンをインキュベートする工程を含む、カンナビノイドグリコシドの製造方法。
- 前記UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼは、配列番号1、3、5、または7に記載の配列を含む、請求項44、48、51、52、および55のいずれか1項に記載の方法。
- 前記Os03g0702000またはOs03g0702000‐様グルコシルトランスフェラーゼは、配列番号9に記載の配列を含む、請求項45、50、および51のいずれか1項に記載の方法。
- スクロースシンターゼとともにインキュベートする工程をさらに含む、請求項43から57のいずれか1項に記載の方法。
- 前記スクロースシンターゼは、配列番号15、17、19、21、23、または25に記載の配列を含む、請求項58に記載の方法。
- 1または2以上のグリコシルトランスフェラーゼを、細胞または植物内で発現させてカンナビノイドアグリコンを生成させる工程、および前記カンナビノイドグリコシドを単離する工程を含む、カンナビノイドグリコシドの製造方法。
- 1または2以上のグリコシルトランスフェラーゼの存在下で、1または2以上の糖供与体とともに、低次のカンナビノイドグリコシドをインキュベートする工程を含む、高次のカンナビノイドグリコシドの製造方法。
- 前記1または2以上のグリコシルトランスフェラーゼは、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼである、請求項61に記載の方法。
- 前記1または2以上のグリコシルトランスフェラーゼは、Os03g0702000またはOs03g0702000‐様グルコシルトランスフェラーゼをさらに含む、請求項62に記載の方法。
- 前記1または2以上の糖供与体は、UDP‐グルコース、UDP‐グルクロン酸、UDP‐マンノース、UDP‐フルクトース、UDP‐キシロース、UDP‐ラムノース、UDP‐フルオロ‐デオキシグルコース、およびこれらの組み合わせからなる群から選択される、請求項61から63のいずれか1項に記載の方法。
- 前記糖供与体は、UDP‐グルコースである、請求項64に記載の方法。
- グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼの存在下で、UDP‐グルコースとともに、低次のカンナビノイドグリコシドをインキュベートする工程を含む、高次のカンナビノイドグリコシドの製造方法。
- グリコシル化が可能である条件下で、第1のグリコシルトランスフェラーゼ、および第2のグリコシルトランスフェラーゼの存在下で、1または2以上の糖供与体とともに、低次のカンナビノイドグリコシドをインキュベートする工程を含む、高次のカンナビノイドグリコシドの製造方法。
- 前記糖供与体は、UDP‐グルコースであり、記第1のグリコシルトランスフェラーゼは、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼであり、および前記第2のグリコシルトランスフェラーゼは、Os03g0702000またはOs03g0702000‐様グルコシルトランスフェラーゼである、請求項67に記載の方法。
- グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼ、およびOs03g0702000またはOs03g0702000‐様グルコシルトランスフェラーゼの存在下で、UDP‐グルコースとともに、低次のカンナビノイドグリコシドをインキュベートする工程を含む、高次のカンナビノイドグリコシドの製造方法。
- 前記低次のカンナビノイドグリコシドは、低次のカンナビノイドグリコシド、低次のエンドカンナビノイドグリコシド、または低次のバニロイドグリコシドである、請求項61から69のいずれか1項に記載の方法。
- 前記方法によって製造された前記高次のカンナビノイドグリコシドは、請求項1から28のいずれか1項に定義される、式(I)の化合物である、請求項61から70のいずれか1項に記載の方法。
- グリコシル化が可能である条件下で、シクロデキストリングルカノトランスフェラーゼの存在下で、マルトデキストリンとともに、低次のカンナビノイドグリコシドをインキュベートする工程を含む、高次のカンナビノイドグリコシドの製造方法。
- グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼおよびシクロデキストリングルカノトランスフェラーゼの存在下で、UDP‐グルコースおよびマルトデキストリンとともに、低次のカンナビノイドグリコシドをインキュベートする工程を含む、高次のカンナビノイドグリコシドの製造方法。
- 前記UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼは、配列番号1、3、5、または7に記載の配列を含む、請求項62、66、69、70、および73のいずれか1項に記載の方法。
- 前記Os03g0702000またはOs03g0702000‐様グルコシルトランスフェラーゼは、配列番号9に記載の配列を含む、請求項63、68、および69のいずれか1項に記載の方法。
- スクロースシンターゼとともにインキュベートする工程をさらに含む、請求項61から75のいずれか1項に記載の方法。
- 前記スクロースシンターゼは、配列番号15、17、19、21、23または25に記載の配列を含む、請求項76に記載の方法。
- グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼの存在下で、UDP−グルコースとともに、低次のグリコシドをインキュベートする工程を含み、
前記低次のグリコシドはステビオールグリコシド以外である、高次のグリコシドの製造方法。 - グリコシル化が可能である条件下で、UGT76G1またはUGT76G1‐様グルコシルトランスフェラーゼの存在下で、アグリコンをUDP−グルコースとともにインキュベートする工程を含む、グリコシドの製造方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562222144P | 2015-09-22 | 2015-09-22 | |
US62/222,144 | 2015-09-22 | ||
US201562245928P | 2015-10-23 | 2015-10-23 | |
US62/245,928 | 2015-10-23 | ||
US201662363808P | 2016-07-18 | 2016-07-18 | |
US62/363,808 | 2016-07-18 | ||
PCT/US2016/053122 WO2017053574A1 (en) | 2015-09-22 | 2016-09-22 | Cannabinoid glycoside prodrugs and methods of synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018528977A true JP2018528977A (ja) | 2018-10-04 |
JP2018528977A5 JP2018528977A5 (ja) | 2019-11-07 |
Family
ID=58387412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018516020A Pending JP2018528977A (ja) | 2015-09-22 | 2016-09-22 | カンナビノイドグリコシドプロドラッグおよび合成の方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11207414B2 (ja) |
EP (1) | EP3352855A4 (ja) |
JP (1) | JP2018528977A (ja) |
CN (1) | CN108136208B (ja) |
AU (1) | AU2016326518B2 (ja) |
BR (1) | BR112018005639A2 (ja) |
CA (1) | CA2999764A1 (ja) |
WO (1) | WO2017053574A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11207414B2 (en) | 2015-09-22 | 2021-12-28 | Graphium Biosciences, Inc. | Cannabinoid glycoside prodrugs and methods of synthesis |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
WO2018176055A2 (en) * | 2017-03-24 | 2018-09-27 | Trait Biosciences, Inc. | High level in vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems |
CA3063186A1 (en) * | 2017-05-09 | 2018-11-15 | Vitality Biopharma, Inc. | Antimicrobial compositions comprising cannabinoids and methods of using the same |
AU2018301674B2 (en) | 2017-07-11 | 2024-03-28 | Trait Biosciences, Inc. | Generation of water-soluble cannabinoid compounds in yeast and plant cell suspension cultures and compositions of matter |
US11946059B2 (en) * | 2017-07-11 | 2024-04-02 | Trait Biosciences, Inc. | In vivo generation of water-soluble cannabinoids in plant cell suspension cultures |
US11905543B2 (en) | 2017-07-11 | 2024-02-20 | Trait Biosceinces, Inc. | In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures |
WO2019082171A1 (en) * | 2017-10-27 | 2019-05-02 | Alvit Pharma | ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY |
US11633484B2 (en) * | 2017-12-21 | 2023-04-25 | Pharmacytics B.V. | Method for improving the oral bioavailability of a drug |
US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
EP3856172A4 (en) * | 2018-09-28 | 2022-10-05 | Visceral Therapeutics Inc. | PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF GASTROINTESTINAL CONDITIONS |
CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
EP3923915A4 (en) * | 2019-02-11 | 2023-03-22 | John Robert Chancey | METHODS OF MAKING AND USING PHYTOCANNABINOIDS COMPLEXED WITH A PROTEIN, PEPTIDE, AMINO ACCHARIDE, POLYSACCHARIDE, DISACCHARIDE, ORMONOSACCHARIDE |
CN109943547B (zh) * | 2019-04-18 | 2022-07-19 | 安徽农业大学 | 一种茶树蔗糖合酶CsSUS587、制备方法及应用 |
US20220290200A1 (en) | 2019-05-27 | 2022-09-15 | Octarine Bio Ivs | Genetically modified host cells producing glycosylated cannabinoids |
CN110201019A (zh) * | 2019-07-17 | 2019-09-06 | 李卫 | 一种用于治疗肌肉痉挛的含有大麻二酚的组合物及其制备方法 |
CN110693027A (zh) * | 2019-10-14 | 2020-01-17 | 桂林莱茵生物科技股份有限公司 | 一种水分散性大麻二酚产品及其制备方法 |
IL294672A (en) * | 2020-01-16 | 2022-09-01 | Cannabis Global Inc | Cannaboside preparation and method for production |
EP4110323A4 (en) * | 2020-02-26 | 2023-12-13 | Graphium Biosciences, Inc. | NEW CANNABINOID GLYCOSIDES AND USES THEREOF |
CN112010924B (zh) * | 2020-09-04 | 2022-09-09 | 中国药科大学 | 新型诺西肽糖基化衍生物及其制备方法和应用 |
CA3197361A1 (en) * | 2020-11-07 | 2022-05-12 | Mathias Schuetz | Production of glycosylated cannabinoids |
CN114573648A (zh) * | 2020-11-30 | 2022-06-03 | 云南汉盟制药有限公司 | 大麻素糖苷及其制备方法 |
US20240058755A1 (en) * | 2020-12-11 | 2024-02-22 | Graphium Biosciences, Inc. | Continuous enzymatic perfusion reactor system |
WO2023053134A1 (en) * | 2021-10-01 | 2023-04-06 | Council Of Scientific & Industrial Research | Cannabinoids c- and o-glycosides possessing anti-proliferative and anti-metastatic properties and process for preparation thereof |
WO2023240221A2 (en) * | 2022-06-11 | 2023-12-14 | Trait Biosciences, Inc. | System and methods for sequential desorption of cannabidiol (cbd) glycoside species |
DE102022004596A1 (de) * | 2022-12-08 | 2024-06-13 | Biosynth Gmbh | Neuartige Cannabinoid-Oligosaccharide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8410064B2 (en) * | 2009-08-24 | 2013-04-02 | The Board Of Trustees Of The University Of Arkansas | Classical cannabinoid metabolites and methods of use thereof |
WO2014122227A2 (en) * | 2013-02-06 | 2014-08-14 | Evolva Sa | Methods for improved production of rebaudioside d and rebaudioside m |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292899A (en) | 1991-11-27 | 1994-03-08 | Synthetic Technology Corporation | Synthesis of 11-nor-Δ-9-tetrahydrocannabinol-9-carboxylic acid glucuronide |
US5627270A (en) * | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
WO2009018389A1 (en) | 2007-07-30 | 2009-02-05 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
JP5551604B2 (ja) | 2007-11-30 | 2014-07-16 | オールトランツ インコーポレイティド | テトラヒドロカンナビノールのプロドラッグ、テトラヒドロカンナビノールのプロドラッグを含む組成物、及び同一のものを使用する方法 |
WO2009158499A2 (en) * | 2008-06-25 | 2009-12-30 | University Of North Texas Health Science Center At Fort Worth | Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems |
MX2011011445A (es) | 2009-04-29 | 2011-11-18 | Univ Kentucky Res Found | Composiciones que contienen cannabinoides y metodos para su uso. |
WO2012011112A1 (en) | 2010-07-22 | 2012-01-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Non psychoactive cannabinoids and uses thereof |
IT1402018B1 (it) | 2010-10-11 | 2013-08-28 | Indena Spa | Formulazioni per il trattamento delle affezioni delle prime vie respiratorie. |
ES2690550T3 (es) | 2011-01-13 | 2018-11-21 | Austin Research Labs Corp. | Dispersiones de alta carga para el tratamiento de infecciones |
CN105209424B (zh) | 2013-01-08 | 2019-12-13 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 氟化的cbd化合物、组合物和其用途 |
US10441617B2 (en) * | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
ES2784229T3 (es) * | 2013-11-20 | 2020-09-23 | Panag Pharma Inc | Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular |
US9497299B2 (en) | 2014-09-18 | 2016-11-15 | Blackberry Limited | Configuring a discard timer |
MA42268A (fr) | 2015-06-23 | 2018-05-02 | Axim Biotechnologies Inc | Compositions antimicrobiennes contenant des cannabinoïdes |
US11207414B2 (en) | 2015-09-22 | 2021-12-28 | Graphium Biosciences, Inc. | Cannabinoid glycoside prodrugs and methods of synthesis |
AU2017250303B2 (en) | 2016-04-15 | 2019-09-26 | Teewinot Technologies Limited | Biosynthesis of cannabinoid prodrugs |
EP3484469B1 (en) | 2016-07-14 | 2024-05-22 | Scisparc Ltd | Compositions and methods of potentiating antimicrobials |
WO2018176055A2 (en) | 2017-03-24 | 2018-09-27 | Trait Biosciences, Inc. | High level in vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems |
CA3063186A1 (en) | 2017-05-09 | 2018-11-15 | Vitality Biopharma, Inc. | Antimicrobial compositions comprising cannabinoids and methods of using the same |
US20200046639A1 (en) | 2017-07-11 | 2020-02-13 | Trait Biosciences Inc. | Consumable water-soluble cannabinoid food and beverage additive having enhanced stability |
-
2016
- 2016-09-22 US US15/762,180 patent/US11207414B2/en active Active
- 2016-09-22 CN CN201680060327.5A patent/CN108136208B/zh active Active
- 2016-09-22 AU AU2016326518A patent/AU2016326518B2/en active Active
- 2016-09-22 EP EP16849598.4A patent/EP3352855A4/en active Pending
- 2016-09-22 BR BR112018005639A patent/BR112018005639A2/pt not_active IP Right Cessation
- 2016-09-22 JP JP2018516020A patent/JP2018528977A/ja active Pending
- 2016-09-22 WO PCT/US2016/053122 patent/WO2017053574A1/en active Application Filing
- 2016-09-22 CA CA2999764A patent/CA2999764A1/en active Pending
-
2021
- 2021-11-16 US US17/527,685 patent/US20220168428A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8410064B2 (en) * | 2009-08-24 | 2013-04-02 | The Board Of Trustees Of The University Of Arkansas | Classical cannabinoid metabolites and methods of use thereof |
WO2014122227A2 (en) * | 2013-02-06 | 2014-08-14 | Evolva Sa | Methods for improved production of rebaudioside d and rebaudioside m |
Non-Patent Citations (4)
Title |
---|
TANAKA,H. ET AL., CURRENT DRUG DISCOVERY TECHNOLOGIES, vol. 8, no. 1, JPN6020022126, 2011, pages 3 - 15, ISSN: 0004634715 * |
TANAKA,H. ET AL., FORENSIC SCIENCE INTERNATIONAL, vol. 106, JPN6020022122, 1999, pages 135 - 146, ISSN: 0004634714 * |
TANAKA,H. ET AL., JOURNAL OF NATURAL PRODUCT, vol. 56, no. 12, JPN6020022119, 1993, pages 2068 - 2072, ISSN: 0004634712 * |
TANAKA,H. ET AL., PLANT CELL REPORTS, vol. 15, no. 11, JPN6020022121, 1996, pages 819 - 823, ISSN: 0004634713 * |
Also Published As
Publication number | Publication date |
---|---|
AU2016326518B2 (en) | 2022-03-24 |
US20220168428A1 (en) | 2022-06-02 |
US20180264122A1 (en) | 2018-09-20 |
CN108136208B (zh) | 2022-07-15 |
BR112018005639A2 (pt) | 2018-10-09 |
AU2016326518A1 (en) | 2018-04-26 |
EP3352855A4 (en) | 2019-05-22 |
CN108136208A (zh) | 2018-06-08 |
EP3352855A1 (en) | 2018-08-01 |
WO2017053574A1 (en) | 2017-03-30 |
US11207414B2 (en) | 2021-12-28 |
CA2999764A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018528977A (ja) | カンナビノイドグリコシドプロドラッグおよび合成の方法 | |
JP6479084B2 (ja) | 一連の糖転移酵素およびその応用 | |
Hultin | Bioactive C-glycosides from bacterial secondary metabolism | |
Lu et al. | AknT is an activating protein for the glycosyltransferase AknS in L-aminodeoxysugar transfer to the aglycone of aclacinomycin A | |
Simkhada et al. | Genetic engineering approach for the production of rhamnosyl and allosyl flavonoids from Escherichia coli | |
Xu et al. | Molecular analysis of the benastatin biosynthetic pathway and genetic engineering of altered fatty acid− polyketide hybrids | |
Hardman et al. | Cannabinoid glycosides: In vitro production of a new class of cannabinoids with improved physicochemical properties | |
EP2571983B1 (en) | Biocatalytic production of glycosides | |
Salcedo et al. | Elucidation of the glycosylation steps during biosynthesis of antitumor macrolides PM100117 and PM100118 and engineering for novel derivatives | |
Parajuli et al. | Regiospecific biosynthesis of tamarixetin derivatives in Escherichia coli | |
Shen et al. | Structural and pharmacological diversity of 1, 4-naphthoquinone glycosides in recent 20 years | |
Liu et al. | Recent advances in methods of puerarin biotransformation | |
Liu et al. | Identification and functional application of a new malonyltransferase NbMaT1 towards diverse aromatic glycosides from Nicotiana benthamiana | |
Zhang et al. | Identification of neuroprotective spoxazomicin and oxachelin glycosides via chemoenzymatic glycosyl-scanning | |
Hoang et al. | Biochemical characterization of recombinant UDP-glucose: sterol 3-O-glycosyltransferase from Micromonospora rhodorangea ATCC 31603 and enzymatic biosynthesis of sterol-3-O-β-glucosides | |
Sun et al. | Synthesis and Antiproliferative Activities of OSW‐1 Analogues Bearing 2”‐O‐p‐Acylaminobenzoyl Residues | |
US20230192748A1 (en) | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | |
US20230346952A1 (en) | Cannabinoid glycoside prodrugs and methods of synthesis | |
KR101717212B1 (ko) | 당전이 효소를 이용한 당 부가된 에스트로겐 수용체 조절제의 제조방법 | |
KR101575295B1 (ko) | 신규한 에포틸론 글리코시드 및 이의 제조방법 | |
KR101704706B1 (ko) | 스테롤 당전이 효소를 이용한 스테롤 글루코사이드의 제조방법 | |
EP2627661B1 (en) | Glycosylated aminocoumarins and methods of preparing and uses of same | |
KR101666667B1 (ko) | 당결합 페녹소다이올 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 | |
CN111138444A (zh) | 一组埃博霉素b葡萄糖苷类化合物及其酶法制备与应用 | |
Chang et al. | Exploring gingerol glucosides with enhanced anti-inflammatory activity through a newly identified α-glucosidase (ArG) from Agrobacterium radiobacter DSM 30147 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190920 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210825 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211109 |